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ABSTRACT  
Elastin is the main structural protein of elastic fibers that allows tissues in vertebrates to extend 
and recoil. Heterozygous loss of function mutations in the elastin gene (ELN) can cause 
supravalvular aortic stenosis (SVAS), a rare obstructive cardiovascular disease typically 
characterized by a narrowing of the ascending aorta. The association of SVAS with hypertension, 
valvular defects and other congenital heart defects (CHDs) is of broader public health 
significance. The main goal of this research is to generate and characterize a set of SVAS-like 
mutant zebrafish lines. Zebrafish have two elastin genes, elna and elnb. First, I investigated the 
genetic and transcript diversity of zebrafish elastins by sequencing 46 and 44 overlapping cDNA 
clones from elna and elnb, respectively. I uncovered substantial variation in from both genes with 
a total of 79 single nucleotide variants (SNVs) in elna and 89 in elnb. In addition, there were 
numerous in-del variants and alternative splicing events. To assess the role of elna in zebrafish 
development, a line of elna homozygous mutants was established.  The mutation (elnasa12235 
c.264T>A, p.Tyr88*) induces nonsense-mediated decay in a developmentally regulated fashion 
with close to complete elimination of the mutant transcript starting at 3 days post-fertilization. 
Phenotypic examination of mutant embryos displayed reduced blood flow, regurgitation, valve 
and heart looping abnormalities. Regurgitation and valve irregularities was also observed in a 
mutant adult male. Histological examination of the hearts in adult elna mutant fish showed 
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 v 
thinning and loss of the elastic cartilage-like morphology in bulboventricular valves.  Further work 
with larger numbers of fish needs to be done, to obtain reliable estimates of the frequency and 
possible sex specificity, and clutch-to-clutch variability of valve and other cardiovascular defects 
in elna mutants.  In conclusion, my studies show extensive sequence variation in elna and elnb. 
Mutants of elna have displayed promise to help explain cardiovascular development and 
detrimental effects of elastin mutations in humans with SVAS especially with respect to cardiac 
valve abnormalities.  
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1.0   INTRODUCTION 
1.1. EXTRACELLULAR MATRIX 
The extracellular matrix (ECM) is a multifaceted, complex network consisting of polysaccharide 
chains, proteoglycans, and glycoproteins, some of which form fibers. It is these constituents that 
allow for a diverse number of structures that make up tissues and support them (Alberts et al., 
2008). 
1.1.1. MAJOR COMPONENTS 
The ECM is produced by a wide variety of cells including fibroblasts, osteoblasts (in bone) 
chondroblasts (in cartilage).  Fibrous proteins of the ECM lie within a “gel-like” substance made 
from polysaccharide glycosaminoglycans (GAGs), that when bound to proteins are called 
proteoglycans and form a scaffold-like structure of highly extended conformations (Alberts et al., 
2008; Hynes & Naba, 2012). It is this complex nature that allows for cellular communication 
between blood and tissue, tissue repair and the passage of nutrients and hormones, while 
endowing tissues with mechanical properties requisite for their diverse functions. Over 300 ECM 
proteins make up the “core matrisome” in mammals, in conjunction with modifying enzymes, 
growth factors, and cytokines. The main components of ECM are proteoglycans, collagens, 
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fibronectins, tenascins, laminins and elastin (Alberts et al., 2008; Bosman & Stamenkovic, 2003; 
Hynes & Naba, 2012).  
1.2. ELASTIC FIBERS 
Elastic fibers are a type of fibrous component of the ECM, critical for tissue flexion, extension and 
resilience. They are found in large part in the cardiovascular system’s large vessels such as the 
aorta and pulmonary artery, the skin, lungs, and elastic cartilage. These dynamic tissues all 
require the ability to extend and recoil repeatedly over a lifetime, with the elastic fibers 
contributing to their unique biomechanical roles (Baldwin, Simpson, Steer, Cain, & Kielty, 2013; 
Kielty, Sherratt, & Shuttleworth, 2002). 
1.2.1. STRUCTURE AND FUNCTION OF ELASTIC FIBERS 
The elastic fibers are insoluble and robust, making it a challenge to understand their biological 
and molecular components. Thanks in part to electron microscopy, genetics, 
immunohistochemistry and biochemical studies, the number of known components has grown 
substantially in recent years (Kielty et al., 2002). The main structural molecules tropoelastin and 
fibrillins work with microfibril and elastic fiber-associated molecules like the latent transforming 
growth factor beta binding proteins (LTBPs), a disintegrin and metalloprotease with 
thrombospontin motifs (ADAMTS) proteins, microfibril-associated glycoproteins (MAGPs), 
fibulins and the lysyl oxidase (LOX) family (Baldwin et al., 2013).  
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Mesenchymal cells and functional necessity dictate the organizational structure of the elastic 
fibers. Mature elastic fibers are composed of an outer microfibrillar network casing, with a core 
of elastin. Microfibrils are composed of fibrillin molecules that mature over time into beaded 
transglutaminase-crosslinked microfibrils of about 10 nm in diameter. The distance between the 
beads in approximately 56 nm and is dependent on calcium and physical tension. These beaded 
microfibrils will assemble into parallel bundles. Tropoelastin, the soluble precursor to polymeric 
elastin is cross-linked and deposited onto microfibril bundles to form elastic fibers (Figure 1). 
When elastic fibers are paired with collagen fibrils, tissues become strengthened and flexible, 
forming a scaffold. The elastin provides the extension and flexibility and the collagen limits the 
extent to which the tissue is stretched (Alberts et al., 2008; Kielty et al., 2002). In addition to 
providing structure, resilience and flexibility, elastic fibers also bind growth factors such as the 
transforming growth factor β (TGFβ) family and influence when it becomes available for use. Cell 
surface receptors, such as integrins, bind components of the elastic fiber to modulate cell fate in 
embryogenesis, cell adhesion, wound healing and tumor growth (Alberts et al., 2008; Baldwin et 
al., 2013; Bosman & Stamenkovic, 2003; Kielty et al., 2002; Midwood & Schwarzbauer, 2002). 
1.2.2. ELASTIC TISSUES 
Blood vessels contain elastic fibers in the form of lamellae that lie between layers of smooth 
muscle cells (SMCs) allowing the vessels to adapt to blood flow. When the elastic properties are  
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Figure 1. Schematic Representation of Elastic Fiber Formation 
A) Fibrillin molecules (black solid lines) mature through cross-linking by transglutaminase into B) 
mature microfibrils (black dotted lines). The beaded fibrils form C) parallel bundles of microfibrils. D) 
The soluble precursor of elastin, tropoelastin (orange dots) is secreted from the cell. Through the 
endothermic process of coacervation, the E) tropoelastin aggregates on the cell surface. F) Lysyl 
oxidase (green oval) facilitates cross-linking (green lines) assembly of the tropoelastin molecules. G) 
The cross-linked tropoelastin is then deposited onto the microfibril bundles, where a mature elastic 
fiber is formed, containing an outer microfibrillar casing and a core of elastin. Diagram is not drawn 
to scale.  
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lost, hypertension and aneurysms can result (Kielty et al., 2002; Wagenseil & Mecham, 2012). In 
the skin, elastic fibers are found in the dermis and make up about 3% of the skin’s dry weight, 
thickening as you proceed from the outer(papillary) to the inner (reticular) dermis. The fibers 
support the skin’s integrity as they extend and recoil over time, maintaining its elasticity 
(Ackerman, Böer, Bennin, & Gottlieb, 2005; Pawlaczyk, Lelonkiewicz, & Wieczorowski, 2013; B. 
Starcher, Aycock, & Hill, 2005). In the lungs, elastic fibers play a role in the development of alveoli, 
lung function and the ability to expand and recoil during breathing. Elastic fibers are found 
throughout the lung interstitium, in the alveolar septa, the walls of the airways and blood vessels 
and in the pleura. Thin and highly branched, they provide support during breathing for normal 
functioning of the lungs (Kielty et al., 2002; Shifren & Mecham, 2006). 
1.2.3. ELASTIN 
Elastin, the main structural protein of elastic fibers is encoded by a single gene in amniotes. The 
human elastin gene contains 34 exons and is located at chromosome 7q11.23 (Fazio et al., 1991). 
The elastin gene encodes multiple soluble precursor proteins, tropoelastins, through the process 
of alternative splicing. Tropoelastins are crosslinked into the insoluble protein polymer of elastin 
in the extracellular matrix (ECM). Due to elastin’s insolubility, it wasn’t until tropoelastin was 
isolated from copper deficient animals with inhibited cross-linking, that its primary structure was 
determined (Gray, Sandberg, & Foster, 1973). 
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1.2.3.1. Tropoelastin structure 
Tropoelastin (TE) is about 70 kDa in size composed of alternating hydrophobic and hydrophilic 
domains. Each domain has a characteristic amino acid composition. Hydrophobic domains, 
accounting for about 82% of tropoelastin’s overall sequence, contain oligopeptide repeat 
sequences between three and six amino acid long and rich in the non-polar amino acids glycine, 
valine, proline and leucine, with VGVAPG (V - valine, G – glycine, A- alanine, P – proline) repeats 
being the most common. Crosslink domains on the other hand contain an abundance of lysines 
involved in crosslinking and alanines which ensure an alpha-helical conformation for the correct 
spacing of lysines (Vrhovski & Weiss, 1998; Wise et al., 2014). It is the flexible hydrophobic 
domains that account for recoil. They have a disordered structure in the relaxed state, with many 
possible conformations, and therefore high entropy. When elastin is stretched, the hydrophobic 
domains become more ordered with reduced entropy (Figure 2). Thus, the recoil of elastin is 
driven by the second law of thermodynamics, which states that entropy of a closed system 
increases with time (Wise & Weiss, 2009).  
 
In addition to hydrophobic and crosslink domains, all vertebrate tropoelastins contain a C-
terminal domain capable of cell adhesion and interaction with other ECM proteins essential for 
elastic fiber formation (Keeley, 2013). The C-terminal region is highly conserved throughout 
evolution, responsible for the assembly of elastic fibers and contains the only two cysteine amino 
acids in all of tropoelastin. The two cysteines create a disulfide bond, that when disrupted, 
hinders fiber assembly (Jensen, Vrhovski, & Weiss, 2000; Vrhovski & Weiss, 1998; Wise et al., 
2014). Tropoelastin (TE) has a moderately conserved sequence, but less conserved especially in 
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the hydrophobic domains from one species to another, suggesting an overall domain character 
is more important (Chung et al., 2006).  
 
 
 
Tropoelastin’s 3-dimensional structure was solved using small angle X-ray and neutron scattering 
experiments to reveal a structure composed of the N-terminus with a coil region, the C-terminus, 
bridge, foot, and hinge (Baldock et al., 2011).  The N-terminal region likely plays a role in the 
protein’s flexibility, structure, coacervation and integration into the ECM scaffold. It also contains 
a coiled region that may directly influence elasticity and the protein’s overall structure. This role 
is also true of the hinge region, which consist of domains 21-23 and does not contain α-helices 
nor β-sheets, allowing it to change conformation. Whereas all other mammalian elastins retain 
RELAXED  
              STRETCHED 
elastin molecule 
cross-link 
Figure 2. Molecular Basis of Elasticity 
In mature elastin, tropoelastin monomers (blue) are crosslinked by desmosine 
or isodesmosine cross-links (pink). The monomers consist of flexible 
hydrophobic domains interspersed with cross-link domains.  The  protein chains 
in elastin remain disordered when in a relaxed state. Entropy is reduced upon 
stretching (below) and a more orderly conformation is obtained.  
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domain 22, in human elastin it is constitutively spliced out. Without domain 22, the structure 
becomes rigid (Yeo et al., 2016). The more recently discovered and still poorly understood bridge 
region encompasses domains 25 and 26, of which 26 is important for coacervation (Wise et al., 
2014).  
1.2.3.2. Biophysical properties of tropoelastin     
Tropoelastin solutions can undergo a reversible phase separation process known as coacervation, 
the formation of droplets with high TE concentration suspended within a solution of low TE 
concentration (Cox, Starcher, & Urry, 1973; Kozel et al., 2006; Partridge, Davis, & Adair, 1955; B. 
C. Starcher & Urry, 1973). Increase in temperature, ionic strength and pH can induce coacervation 
(Ostuni, Bochicchio, Armentano, Bisaccia, & Tamburro, 2007; Vrhovski, Jensen, & Weiss, 1997) 
as can biomolecules such as  GAGs, especially heparan sulfate (Y. Tu & Weiss, 2008, 2010), and 
integrins on the surface of cells.  In vitro studies have shown that the process of coacervation 
occurs in two phases. The first phase is reversible, where the TE exists as a monomer and depends 
on a narrow window of temperature to begin assembling into a polymer as elastin. The second 
phase, maturation, is irreversible and has been shown through in vitro experiments to take place 
when temperatures reach levels close to normal body temperature of 37oC and a pH of 7 and 
kept for extended periods of time, allowing the coacervate to mature and tropoelastin molecules 
to more tightly bind each other (Bressan et al., 1986; Vrhovski et al., 1997; Vrhovski & Weiss, 
1998).  
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1.2.3.3. Elastin crosslinking, longevity and degradation    
Tropoelastin is secreted from smooth muscle cells, a variety of fibroblasts, and elastic 
chondrocytes and taken to the cell surface by elastin binding protein where it forms into globules, 
which are intermediate structures of elastic fiber formation (Czirok et al., 2006; Kozel et al., 
2006). Next, the globules are deposited onto microfibrils and fused through active cell 
movements to make larger, branched structures stabilized by cross-linking. Lysyl oxidase (LOX) 
enzymes are needed to initialize the cross-linking through oxidizing of the lysine residues to 
produce α-amino adipic δ-semialdehyde (allysine). This is followed by spontaneous reactions 
forming cross-links, especially tetrafunctional desmosine and isodesmosine which are unique to 
elastin. Each is composed of three allysines and one lysine residue (Kagan & Li, 2003; Vrhovski & 
Weiss, 1998). It is the cross-linking that leads to a stable, mature elastin.  
 
Elastin is produced early and has a long half-life. For example, human lung elastin has a mean 
carbon residence life of 74 years (Shapiro, Endicott, Province, Pierce, & Campbell, 1991). This 
longevity is partially explained by the resistance of elastin to degradation by most proteases. 
However, some proteases, called elastases, can degrade elastin and include the serine proteases 
neutrophil elastase, pancreatic elastase and cathepsin G as the most commonly seen in mammals 
(Vrhovski & Weiss, 1998). Matrix metalloproteinases (MMPs) -2, -9 and -12 also play a role in 
elastolysis (Van Doren, 2015). Controlled degradation of elastin is important for its other 
functions in wound healing, growth and tissue remodeling. 
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1.2.3.4. Expression and regulation of elastin    
Studies of human skin fibroblasts, sheep ligaments, rat lungs and chick aorta have shown that 
mRNA expression and synthesis of elastin is highest during early development. Both the amount 
of mRNA and TE synthesis seem to impact how much elastin is made, possibly inhibiting its 
production if excess TE is accumulated in the ECM. In humans, the 5’-flanking region contains 
various transcription factor binding sites and activators, a CAAT promoter but no TATA box. 
Complementary RNA sequencing has shown that the elastin gene (ELN) has multiple transcription 
start sites. Comparison of transcript and gene sequences revealed substantial alternative splicing 
(Rosenbloom et al., 1991; Vrhovski & Weiss, 1998). 
 
Elastin synthesis studies have shown a wide array of modulators that regulate elastin expression. 
In cell culture studies, soluble factors such as transforming growth factor-β (TGFβ) (Kahari, Olsen, 
et al., 1992; Kuang et al., 2007), insulin-like growth factor-I (IGF-I) (Badesch, Lee, Parks, & 
Stenmark, 1989), and interleukin-1β (IL-β) (Mauviel et al., 1993) upregulate expression of elastin 
(Milewicz, Urban, & Boyd, 2000). Tumor necrosis factor-α (TNF-α) (Kahari, Chen, Bashir, 
Rosenbloom, & Uitto, 1992), interferon-γ by inhibition of LOX (Song, Ford, Gordon, & Shanley, 
2000), and vitamin D3 (Pierce, Kolodziej, & Parks, 1992) down-regulate elastin (Comper, 1996; 
Milewicz et al., 2000). Vitamin D3’s effect on elastin was also demonstrated in a rabbit model. 
When an overdose of D3 was delivered transplacentally, the rabbits displayed SVAS-like 
pathology (Friedman & Roberts, 1966; Milewicz et al., 2000). 
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1.2.3.5. Alternative splicing of elastin    
Elastin transcripts show significant variation (Indik et al., 1987). Alignments of human elastin have 
shown six exons to display some form of alternative splicing, with early alignments differing only 
in small segments of sequence (Uitto, Christiano, Kahari, Bashir, & Rosenbloom, 1991). Generally, 
there are two types of alternative splicing observed (Figure 3): 1. Complete excision of an exon, 
demonstrated by human exons 22, 23, and 32.  2. Only a portion of the exon is excised, through 
the use of either the 5’ donor or 3’ acceptor site, as seen with exon 26A. Extensive alternative 
splicing produces numerous isoforms of tropoelastin in humans. In some species such as the cow, 
the frequency of alternative splicing is up-regulated as the cow ages, seen more in adults than in 
the calf, demonstrating that developmental stage influence this process (Vrhovski & Weiss, 
1998). Studies of various species have shown that alternative splicing is common, but species 
specific, and tissue-specificity has yet to be determined for the differing isoforms (Chung et al., 
2006; Keeley, 2013). 
 
A B 
 
Figure 3. Types of Alternative Splicing Observed in Elastin 
A) Complete excision of an exon. B) Portion of the exon is excised through an alternative 5’ donor site.  
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1.2.3.6. Evolution of elastin  
The evolution of elastin can be explained either through the conservation of the elastin sequence 
or the functional requirements of a species and its environment. The origin of tropoelastin is still 
unclear. Elastin is present in vertebrates, but absent in lower chordates and invertebrates, 
making it a rather new constituent of the ECM compared to collagens and fibrillins (Keeley, 2013). 
Elastin evolution has involved expansion of domains, making alignments of various species’ entire 
elastin sequence futile. Variability in the sequence does not permit for alignment of mammalian, 
avian, amphibian and teleost tropoelastin, except for in the C-terminus where the amino acid 
sequence appears to be conserved throughout evolution (Chung et al., 2006; Keeley, 2013). 
Because of this, researchers have concentrated on sequence alignment scores instead. The result 
was clustering of exons from either the same species or between exons of similar structure; 
hydrophobic or cross-linking domains with minimal overlap between the two domain types. 
Extensive exon duplication can also be seen, for example, a 6-times multiplication of hydrophobic 
and crosslink exon pairs representing exons 20-31 in zebrafish (Danio rerio) elna (He et al., 2007). 
While there were certain motifs found throughout the various species, such as VPGVG for 
assembly coacervation and elasticity (Pepe et al., 2005), or PGVGA or PGVGV for self-assembly 
with fibrils, some motifs such as PGVGVA or GGVGVA resulted in abnormal tropoelastin 
aggregates in model peptides (He et al., 2007). However, it should be noted that short peptides 
may have different material behaviors when studied by themselves as opposed to in the context 
of the full-length TE molecule. Aside from the specific domain motifs found in elastin and TE, 
elastin may have adapted to a variety of species or taxons to fill a special functional role (Chung 
et al., 2006; Keeley, 2013). For example, in teleosts, elastin b (elnb) has evolved as a form of TE 
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specific to the bulbus arteriosus (BA) which helps regulate the pulsating pressure and protects 
the gills (Miao, Bruce, Bhanji, Davis, & Keeley, 2007).  
 
Elastin’s appearance coincides with the development of closed circulatory systems in higher 
organisms (R. P. Mecham, 2018). Amniotes and teleosts have vastly different blood pressures. 
The systolic blood pressure  in humans and mice is 120 mmHg (Wang et al., 2013), whereas the 
rainbow trout has a systolic blood pressure of 35mmHg (Stevens & Randall, 1967; Wang et al., 
2013). The elongation of hydrophobic domains in the teleosts may have allowed adaptation to 
altered physical demands. This is also demonstrated in zebrafish and other species with two eln 
genes (paralogues). The paralogue most similar to other organisms, elna, is expressed in the 
vascular tissue and functions similarly to other vertebrate elastins. In contrast, elnb has further 
diverged to have a specific function in the BA of teleosts (Keeley, 2013; Miao et al., 2007).  
 
Elastin may have also adapted over time to function in varying environmental temperatures to 
allow for coacervation to take place at lower temperatures than the body temperatures of 
mammals. Frog and teleost elastin has a higher molecular weight and large numbers of repetitive 
exons, which are predicted to lower the coacervation temperature of tropoelastin. Elastin 
evolution is also seen in the extension and recoil cycles of heart and lungs, and varying heart 
rates of mammals. As with blood pressure, the rate at which a heart beats also varies widely, 
even among mammals alone; ~30 beats per minute in a whale to ~500 beats per minute in a 
mouse (Gosline, 1980). The TE sequence and rearrangements throughout evolution may be in 
part due to a response to the differing range of extension and recoil under which it must operate 
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(Keeley, 2013). These adaptations to tropoelastin throughout evolution may also be of 
significance in maintaining the integrity of elastic fibers, but more research is needed to show if 
such factors affect the matrix structure over time. 
1.2.4. ELASTIC FIBER ASSEMBLY 
Elastic fiber assembly is a complex, hierarchical process involving a number of proteins and their 
accessories early in development. They are made up of two ultra-structurally distinct 
components of the elastic fibers: an outer microfibrillar sheath composed of fibrillins and other 
accessory proteins that serve as a template which elastin can bind though its C-terminal domain, 
and an inner elastin core (Sato et al., 2007). To begin the process, fibrillin must form close to the 
cell surface into beaded microfibrils that mature to form parallel bundles of cross-linked 
microfibril regions. The elastin precursor, tropoelastin, then undergoes the process of 
coacervation which allows for proper alignment tropoelastin monomers for cross-linking by lysyl 
oxidase. Coupled to cell motion in a hierarchical, coordinated manner, the TE globules aggregate 
creating larger elastic fiber structures (Czirok et al., 2006; Kielty et al., 2002).  
 
Elastin binding protein (EBP), integrins and GAGs, play integral parts in tropoelastin’s ability to 
bind cells. It is through the C-terminal domain that tropoelastin interacts with GAGs and integrins 
to mediate fibroblast adhesion to tropoelastin. The EBP has a role in modulating cell behavior 
and assists with alignment of tropoelastin during self-assembly and preventing degradation of 
the protein (Almine et al., 2010).   Although deposited mainly during late fetal stages and into 
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early neonatal periods, production of tropoelastin can be reactivated in the event of injury (Wise 
& Weiss, 2009). It also has the ability of influencing cell signaling and adhesion.  
 
Further cross-linking of elastin creates a network of fibers facilitated by LOX, latent TGFβ binding 
proteins (LTBPs) and fibulins, especially fibulin-4, to form the insoluble elastin core. This process 
of elastic fiber formation is referred to as “macro-assembly” (Baldwin et al., 2013). Elastic fiber 
formation can be tissue specific, depending on functional differences among tissues (Kielty et al., 
2002). Elastic fibers that are not assembled correctly are the source of various diseases.  
1.3. DISEASES CAUSED BY ELASTIN GENE MUTATIONS 
Elastin is synthesized early during development and has remarkable longevity required for 
maintaining its function throughout life (Shapiro et al., 1991).  Consequently, many common age-
related diseases including hypertension (Arribas, Hinek, & Gonzalez, 2006), aneurysms (Halloran 
& Baxter, 1995) and emphysema (Shifren & Mecham, 2006) are associated with loss of 
compliance and gradual breakdown of elastin in tissues (Uitto, Ryhanen, Abraham, & Perejda, 
1982). Human genetic studies provide evidence that elastic fiber abnormalities are not simply 
associated with age-related cardiovascular, pulmonary and connective tissue diseases, but can 
also cause them. Mutations in the elastin gene (ELN) can cause supravalvular aortic stenosis 
(SVAS) through a heterozygous loss of function mutation, and autosomal dominant cutis laxa 
(ADCL) by means of mutant elastin synthesis.   
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1.3.1 AUTOSOMAL DOMINANT CUTIS LAXA (ADCL) 
Autosomal dominant cutis laxa (ADCL, OMIM #123700) is characterized by redundant, sagging 
and inelastic skin, aortic aneurysms, and emphysema and is caused by ELN mutations resulting 
in the synthesis of mutant elastin (Callewaert et al., 2011; Szabo et al., 2006; Urban, Gao, Pope, 
& Davis, 2005).  
1.3.1.1. Clinical manifestations, natural history and management    
Unlike the more severe autosomal recessive forms of cutis laxa, that sometimes leads to 
childhood death, ADCL manifests itself in a range of systems with mild to severe phenotypic 
results. In addition to the common loose, sagging skin that may worsen with age, typical facial 
features include a high forehead, enlarged earlobes and a beaked nose (Berk, Bentley, Bayliss, 
Lind, & Urban, 2012). Other systemic manifestations may encompass the gastrointestinal, 
pulmonary and cardiovascular systems with problems such as hernias, artery stenosis, dilation 
and tortuosity and emphysema (Tofolean et al., 2015; Weir, Joffe, Blaufuss, & Beighton, 1977). 
Management of systemic lesions and preventative checkups involving echocardiography and 
pulmonary function tests should be conducted to prevent complications. (Berk et al., 2012). 
1.3.1.2. ELN Mutations in ADCL    
Most ADCL-related mutations cause a frame-shift within the last 5 exons of ELN resulting in the 
production of a mutant tropoelastin where the C-terminus is replaced by an extended peptide 
sequence translated in the new reading frame past the wild type stop codon (Callewaert et al., 
2011). This mutant protein has enhanced self-association properties but diminished binding 
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microfibrils, and thus interferes with elastic fiber formation in a dominant negative or a toxic gain 
of function manner (Callewaert et al., 2011; Q. Hu et al., 2010). 
1.3.1.3. Molecular mechanisms of ADCL    
Mouse models for ADCL have shown enlargement of airspace, emphysema, respiratory distress 
through a decrease in stiffness of the lung tissue, and premature death, but no skin abnormalities 
or cardiovascular pathologies (Q. Hu et al., 2010). Although increased endoplasmic reticulum (ER) 
stress and elevated TGFβ signaling have been found in both human cells and a mouse model of 
ADCL, it remains unclear if these pathways contribute to the disease or if they could be targeted 
in treating ADCL. 
1.3.2 SUPRAVALVULAR AORTIC STENOSIS (SVAS) 
Supravalvular aortic stenosis (SVAS; OMIM 185500) is an obstructive cardiovascular disease 
affecting 1 in 20,000 live births causing a narrowing of the aorta and hypertension (Baldwin et 
al., 2013; Metcalfe et al., 2000). It is caused by a heterozygous loss of function mutation in the 
elastin gene (ELN) and is inherited autosomal dominantly. SVAS is a progressive disease with 
incomplete penetrance and variable expressivity (Merla, Brunetti-Pierri, Piccolo, Micale, & 
Loviglio, 2012; Metcalfe et al., 2000; Park, Seo, Yoo, & Kim, 2006; Pober, Johnson, & Urban, 2008; 
Wagenseil & Mecham, 2012). 
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1.3.2.1. Clinical manifestations, natural history and management    
SVAS manifests at birth or in childhood as a narrowing of the ascending aorta and can be seen on 
its own as an isolated disease, or as part of Williams-Beuren syndrome (WBS; OMIM 194050). 
WBS is a complex developmental disorder associated with neurobehavioral, craniofacial, 
cardiovascular and metabolic abnormalities, caused by a microdeletion up to 1.8Mb in size at 
7q11.23, a region that contains 27 genes including ELN (Merla et al., 2012; Micale et al., 2010; 
Pober et al., 2008).  
 
The primarily affected artery in those with non-syndromic SVAS is the aorta, with thickening of 
the media (Figure 4) at the sinotubular junction (Figure 6) and can extend towards the ascending, 
transverse arch and descending aorta (McElhinney, Petrossian, Tworetzky, Silverman, & Hanley, 
2000; Scott et al., 2009). Other branches such as those of the pulmonary (Figure 5, Figure 6) or 
coronary arteries have been observed with narrowing of the lumen as well, so determining the 
extent of vascular involvement is important in management of this disease. Patients typically 
present with a systolic murmur, although one is not always present, and become symptomatic 
by the age of twenty. Cases are divided into three categories with two of the lesions present as 
a physiological invagination: stenosis only present as a fibrous ring above the valve (10%), a 
diffuse narrowing of the ascending aorta with medial thickening (20%), and the most common 
type is an hourglass shaped stenosis that has medial layer thickening and sometimes 
accompanied by a thickened, fibrous intimal layer (70%). The stenosis of the artery causes blood 
pressure to become elevated in the left side of the heart, accompanied by enlargement and 
thickening of the cardiac muscle (Merla et al., 2012; Milewicz et al., 2000). 
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Figure 4. The Structure of an Artery Wall 
Non-syndromic SVAS primarily affects the aorta and includes a thickening of the tunica 
media, made up of smooth muscle cells and elastin. Thickening of the media leads to 
a narrowing of the lumen. Blausen.com staff (2014). “Medical gallery of Blausen 
Medical 2014”. WikiJournal of Medicine 1 (2). DOI: 10.15347/wjm/2014.010. ISSN 
2002-4436. 
 
 
Figure 5 Anatomy of the Human Heart 
The aorta is the primary affected vessel in SVAS, although other arteries including the 
pulmonary and coronary arteries may also contain a narrowing of the lumen. 
Blausen.com staff (2014). "Medical gallery of Blausen Medical 2014". WikiJournal of 
Medicine 1 (2). DOI:10.15347/wjm/2014.010. ISSN 2002-4436 
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Figure 6 Segments of the Human Aorta 
 
Diagnosis is best confirmed by echocardiography or a magnetic resonance angiography (MRA). 
Children diagnosed early benefit from timely surgical intervention to repair the diseased artery 
(Greutmann et al., 2012). However, surgical repair during infancy can be challenging and at higher 
risk of mortality if accompanied by concomitant lesions (Mitchell & Goldberg, 2011). In a group 
study of 113 adults, 55% of which had WBS, those without WBS had an increase in the severity 
of SVAS and associated more often with left ventricular outflow tract obstructions. Patients with 
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WBS displayed more often with mitral valve regurgitation. The study also found that adults 
remained at risk for cardiac complications and reoperation of the valve, but progression of the 
disease was rare (Greutmann et al., 2012). 
 
The presenting aortic manifestations have been addressed as follows in some patients: removal 
of the affected area of the artery; balloon aortic catheter procedure to attempt to widen the 
stenosis; or incision of the artery to the root and augmentation with a tissue graft. No one type 
of surgical technique has shown to have an advantage over others in long term studies if the 
appropriate measures are taken to address the most prominent issue (McElhinney et al., 2000; 
Scott et al., 2009). Left untreated, SVAS has the potential to evolve into cardiac failure or death 
(Merla et al., 2012; Yeo, Keeley, & Weiss, 2011). 
1.3.2.2. ELN Mutations in SVAS    
Patients with SVAS have shown premature termination (nonsense or frameshift) mutations; 
some have splice site and very few have missense mutations or large deletions or translocations 
with breakpoints in the ELN gene (Metcalfe et al., 2000; Micale et al., 2010; Milewicz et al., 2000; 
Yeo et al., 2011). ELN gene mutations in SVAS often lead to a truncated reading frame and 
nonsense-mediated decay of the mutant transcript resulting in an inactive, null allele (Dietz & 
Mecham, 2000; Urban et al., 2000; Yeo et al., 2011). The amount of tropoelastin secreted can be 
decreased in those with a splice site mutation (Urban et al., 1999). Alternatively, tropoelastin is 
secreted at normal levels but coacervation and assembly of the elastic fibers is hindered (Wachi 
et al., 2007; Wu & Weiss, 1999).  
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1.3.2.3. Molecular mechanisms of SVAS    
The most widely supported molecular mechanism for SVAS is haploinsufficiency of the ELN gene 
(Baldwin et al., 2013; Micale et al., 2010). The haploinsufficiency can result from loss of an allele, 
unstable mRNA due to nonsense-mediated mRNA decay, or mutant protein production that 
hinders elastic fiber assembly (Dietz & Mecham, 2000). In a study conducted on patients with 
either isolated SVAS or syndromic WBS, patients exhibited a reduction in elastin mRNA levels 
resulting in low amounts of insoluble elastin deposition. In both cohorts, low levels of insoluble 
elastin in the artery walls led to an increase in proliferation of arterial SMCs and multilayer 
thickening of the tunica media, indicating that insoluble elastin is important for the regulation 
vascular cell division (Urban et al., 2002). 
 
Mouse models have also been used extensively to study the molecular mechanisms of SVAS. Mice 
lacking elastin (Eln-/-) due to a deletion of exon 1 and a portion of the promoter region, exhibited 
a perinatal lethal phenotype with an increase in vascular wall SMC proliferation that obstructed 
the artery lumen (Li, Brooke, et al., 1998). A model hemizygous for ELN (Eln+/-), like that seen in 
SVAS human patients did not have an obvious phenotype and had similar appearance and 
longevity when compared to the wildtype (Eln+/+) mice. Upon closer inspection of the vessels, the 
hemizygous mice had a 50% decrease in Eln mRNA at birth, with thinner lamellae. Although not 
all human SVAS characteristics were displayed, changes in the arterial wall was similar with 
characteristically increased number of lamellae, and increased blood pressure (Li, Faury, et al., 
1998). A third study in an SVAS mouse model found an increase in integrin levels in the aorta of 
Eln-/- mice. Integrin β1 was increased in the endothelial cells and some SMCs of the outer smooth 
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muscle layers, and integrin β3 was up-regulated in SMCs of the medial layer of the Eln-/-  aorta 
causing narrowing of the lumen. Inhibition of integrin β3 reduced the hyper-muscularization and 
stenosis (Ashish Misra et al., 2016). Results seen in these murine models suggest that the absence 
of elastin has effect on cell proliferation, adhesion and fate determination through 
downregulation of integrin expression and signaling. Fibrillins are potent ligands of integrins (Bax 
et al., 2003), therefore, elastin may inhibit integrin signaling by masking integrin ligands on 
microfibrils as a part of elastic fiber formation.  
 
Although other congenital heart defects (CHD) such as mitral valve prolapse, mitral valve 
insufficiency and bicuspid aortic valves are less common in WBS compared to SVAS (Lacro & 
Smooth, 2006) studies have nonetheless shown that elastin haploinsufficiency can affect valve 
development. Eln+/- mice had normal ECM organization except for in the aorta at birth. As the 
mice aged, valves became thin and elongated with increased ECM disorganization, tensile 
stiffening, increased valve interstitial cell proliferation and elastin fragmentation. Valve disease 
which included regurgitation in the aortic valve became progressively worse in the ELN+/- mice, 
with 70% of older adults displaying the valve abnormalities, establishing elastin’s role in valve 
pathogenesis. These same mice also exhibited a decrease in TGF-β signaling in cardiac valves 
(Hinton et al., 2010).  
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1.4. CARDIOVASCULAR DEVELOPMENT IN ZEBRAFISH 
As a disease model, zebrafish have come to be widely used for developmental biology studies 
due to their external fertilization, large numbers of offspring, and access to all stages of rapid 
development. Zebrafish embryos are transparent, and the heart is located in a prominent ventral 
position that allows for noninvasive in vivo observation of the cardiovascular system from the 
time of fertilization throughout the heart and vasculature’s development in the embryo (Bakkers, 
2011; Bournele & Beis, 2016; Lieschke & Currie, 2007; Nguyen, Lu, Wang, & Chen, 2008; S. Tu & 
Chi, 2012). Another advantage is the ease with which the developing embryo is able to be imaged. 
Fluorescent transgenic lines allow for easy visualization of cardiac and smooth muscle cells to 
determine cell differentiation (Bakkers, 2011; Lieschke & Currie, 2007). Zebrafish are also not 
dependent on the cardiovascular system within the first 7 days of life. Oxygen is acquired in 
sufficient amounts through passive diffusion (Pelster & Burggren, 1996), facilitating analysis of 
cardiac valve formation and the effects of mutations that would otherwise be lethal in mammals 
(Bournele & Beis, 2016). When compared to human cardiac disease-related genes, the Online 
Mendelian Inheritance in Man (OMIM) database shows that at least 82% of those genes contain 
at least one zebrafish ortholog. These genes are easily manipulated in the zebrafish and provide 
opportunities to study their function, especially in diseases of the cardiovascular system’s 
development (Asnani & Peterson, 2014). 
 
In vertebrates, the heart is the first functional organ formed (Moorman, Webb, Brown, Lamers, 
& Anderson, 2003; Schroeder, Jackson, Lee, & Camenisch, 2003). The zebrafish heart is made up 
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of four compartments that pump deoxygenated blood to the gills for oxygenation. The four parts 
are the sinus venosus, the atrium, the ventricle and the bulbus arteriosus (N. Hu, Sedmera, Yost, 
& Clark, 2000). The bulbus arteriosus is an elastic reservoir seen in the teleost outflow tract (OFT), 
comprised of smooth muscle cells and abundant elastic fibers, that absorbs high volumes of blood 
and prevents gill damage due to high blood pressure. (Grimes, Stadt, Shepherd, & Kirby, 2006; 
José M. Icardo, 2017; S. Tu & Chi, 2012).  
 
Despite the human heart containing four chambers (two atria and two ventricles), and the 
absence of a separate pulmonary circulatory system in the zebrafish (S. Tu & Chi, 2012), there 
are similarities between the two chambers in zebrafish to those of the human that may lead to a 
better understanding of cardiovascular pathologies (Asnani & Peterson, 2014). Both humans and 
zebrafish undergo similar cardiovascular morphogenetic development (Figure 7). The cardiac 
cells of zebrafish start off laterally and migrate to the midline during segmentation to form a 
primitive heart tube. The heart tube develops through formation of a cardiac disc structure fused 
at the midline. This is followed by cardiac looping at 36 hours post fertilization (hpf) where it 
differentiates into the chambers. Development is rapid and by 24 hpf, the embryo’s primitive 
heart tube begins peristatic contractions which transition to coordinated chamber contractions 
by 48 hpf (Bakkers, 2011; Nguyen et al., 2008; Yelon, 2001). 
The valves of the zebrafish heart appear at 5 dpf (N. Hu et al., 2000) but they are not mature, 
developing further in two phases. During the initial phase through 16 dpf the valves elongate, 
followed by maturation in which the ECM collagen and elastin deposits thicken the valve 
structures (Martin & Bartman, 2009). 
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Some examples of how zebrafish express mutations analogous to human cardiovascular disease 
are as follows: the gridlock mutation (grl) in the hey2 gene causes circulation development to fail 
by blocking aortic blood flow through occlusion of the proximal aorta, as seen in human aortic 
coarctation (Weinstein, Stemple, Driever, & Fishman, 1995; Zhong, Rosenberg, Mohideen, 
Figure 7. Stages of Cardiac Development  
A) The cardiac progenitor cells (pink and blue) of zebrafish start off laterally and migrate to the midline 
during segmentation to form a primitive heart tube (D). The heart tube develops through formation 
of a cardiac disc structure fused at the midline and the endocardium (green) forms the inner lining. 
This is followed by cardiac looping (F) at 36 hours post fertilization (hpf) where the ventricle moves 
towards the midline and the structure differentiates into the chambers. Looping continues and forms 
an S-shaped loop (G). Development is rapid and by 24 hpf, the embryo’s primitive heart tube begins 
peristatic contractions which transition to coordinated chamber contractions by 48 hpf. Bakkers, J. 
(2011). Zebrafish as a model to study cardiac development and human cardiac disease. Cardiovasc 
Res, 91(2), 279-288. doi:10.1093/cvr/cvr098. Obtained for use with permission from publisher. 
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Weinstein, & Fishman, 2000). Symptoms similar to human arrhythmias of type 2 long QT, where 
the atrium contracts twice and the ventricle once, are seen in fish of the breakdance (bre) 
mutation (Chen et al., 1996; Langheinrich, Vacun, & Wagner, 2003). 
 
Zebrafish have also shown to be important in understanding advanced heart failure and end-
stage cardiomyopathy in humans and could provide future insight into small molecule drug 
treatments. Adult zebrafish have the ability to regenerate their ventricular tissue through 
dedifferentiation of cardiomyocytes, where cells revert to earlier developmental stages, and 
express a molecular marker important in cardiac development, gata4 (Asnani & Peterson, 2014; 
Jopling et al., 2010; Kikuchi, 2014; Kikuchi et al., 2010). 
 
Mutations in zebrafish also have the potential to increase the understanding of certain 
cardiovascular developmental regulations in the human and may help explain how embryonic 
myocardial function mutations lead to congenital heart disease in humans and impact valve 
development (Asnani & Peterson, 2014; Bartman et al., 2004). Embryos with the silent heart  
(sih-/,- or tnnt2a) and cardiofunk (cfk-/-) mutations, have irregularities in valve development and 
lack contraction as well as early blood flow (Bartman et al., 2004). A separate study has shown 
that endocardial cells differentiate in response to Notch signaling before the mesenchyme in 
valve formation (Beis et al., 2005). With the ability to easily observe cardiovascular development 
in the zebrafish, various groups have identified numerous genes that regulate cardiac patterning, 
cell fate determination and morphogenesis at various stages (Chen et al., 1996; Singh et al., 2016; 
Stainier et al., 1996; Yelon, 2001) (Table 1). 
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Table 1. Examples of Genes Related to Zebrafish Cardiovascular Development 
  
Zebrafish 
Gene 
Name 
Phenotype Zebrafish Mutant 
Human 
Gene 
Name 
Related Human 
Cardiovascular 
Disease 
Reference 
hey2  
alias: grl 
circulation fails to 
develop, blockage of 
aortic bloodflow 
Gridlock  
(grl-/-) 
HEY2 aortic 
coarctation 
(Weinstein et 
al., 1995; 
Zhong et al., 
2000) 
bre type 2 arrhythmia  
(long QT) 
Breakdance 
(bre-/-) 
 type 2 
arrhythmia 
(Chen et al., 
1996; 
Langheinrich et 
al., 2003) 
tnnt2a  lack of 
contractility/heart beat 
Silent heart 
(sih-/-) 
TNNT2 Familial 
hypertrophic 
cardiomyopathy 
(Bartman et al., 
2004) 
acta1b cardiac dilation and no 
early bloodflow 
Cardiofunk 
(cfk-/-) 
ACTA1 structural 
congenital heart 
disease 
(Bartman et al., 
2004) 
tbx2b impaired heart valve 
formation 
Ping pong 
(png+/-) 
TBX2 -- (Just, Hirth, 
Berger, 
Fishman, & 
Rottbauer, 
2016) 
ugdh heart valve formation 
initiation impaired 
Jekyll 
(jek-/-) 
UGDH -- (Walsh & 
Stainier, 2001) 
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1.5. ZEBRAFISH AS A MODEL IN ELASTIN STUDIES 
Zebrafish offer further advantages for elastin studies. Peak elastin expression occurs during the 
late fetal and early perinatal period in mammals (Kelleher, McLean, & Mecham, 2004) when the 
animals are less accessible to experimental manipulations. In contrast, zebrafish embryos and 
larvae have developmental stages with peak elastin expression (Miao et al., 2007) that are 
continually accessible and amenable to in vivo imaging. While the zebrafish elastin genes have 
been sequenced in their entirety, for comparison to each other and other species (Chung et al., 
2006; He et al., 2007), little has been published regarding the diversity of these gene transcripts 
in zebrafish. 
 
A limitation of zebrafish in genetic studies is that many of the human genes have two paralogs in 
zebrafish. Zebrafish have two tropoelastin genes, elna and elnb, due to whole-genome 
duplication in teleosts (Chung et al., 2006).  The orthologous relationships are sometimes 
challenging to establish, but not so for elastin, where sequence similarity, the size of the encoded 
protein and expression pattern supports elna (Table 2) as the ortholog of human elastin (Keeley, 
2013; Miao et al., 2007). Nevertheless, work on both elastin genes is of importance, as localized 
expression of elnb to the bulbus arteriosus (outflow tract of the heart), presents an opportunity 
to obtain mutants with phenotypes limited to this organ.  
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         Table 2. Human and Zebrafish Elastin Genes 
 
 Human  Zebrafish  (2 genes) 
Gene(s) ELN elna  elnb 
Exons 34 exons 56 exons 58 exons 
Location 7q11.23 chromosome 15 chromosome 21 
Coding  
sequence size 2.3kb 3.5kb 6.2kb 
Protein weight 69kDa ~100 kDa ~170 kDa 
 
 
 
There is some overlap of elastin expression in the zebrafish larvae. Previous research has shown 
that elna first appears in the brain at 1-day post fertilization (dpf). At 2 dpf it is in the cerebral 
ventricles, at 3 dpf it is present in the bulbus arteriosus (BA) and outflow tract and by 4 dpf elna 
is in the swim bladder. On the other hand, elnb does not appear until 3 dpf in the BA. At 4 dpf it 
is in the cranium, BA and in the swimbladder at 5 dpf. Both elna and elnb peak at 6-7 dpf, but 
elna is only expressed 24 times stronger at this time point than at 1 dpf, while elnb is 300 times 
more expressed. Transcript abundance begins to decrease at 8 dpf and reaches a basal expression 
at 23 dpf in both genes (Miao et al., 2007). Recently, zebrafish elnb morphants and mutants were 
found to have cardiac outflow tracts populated by cardiomyocytes instead of smooth muscle cells 
observed in control fish, indicating that elnb is essential for correct cell fate decisions in the 
developing teleost heart (Moriyama et al., 2016).  
 
While research has been done on the development of the cardiovascular system in zebrafish, not 
much is known about elastin’s role in its development, especially the valve leaflets. In humans, 
the valve cusps contain about 50% collagen and 13% elastin (Bashey, Torii, & Angrist, 1967). In 
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porcine aortic valve leaflets, elastin is required to maintain tissue integrity and to assist in 
returning the valves to their original shape through recoil once pressure from blood flow has 
ceased (Vesely, 1998). Research conducted in the teleost family, which includes zebrafish, has 
shown that the atrioventricular (AV) region of the heart gives rise to the valves through signaling 
pathways, conserved from zebrafish to mammals (J. M. Icardo & Colvee, 2011). The Notch 
pathway regulates bone morphogenetic protein (Bmp) signaling and defines the atrioventricular 
canal and inner curvature areas of the heart (Rutenberg et al., 2006). Notch (Timmerman et al., 
2004), Wnt/β-catenin (Hurlstone et al., 2003), ltbp3-TGFβ (Zhou et al., 2011) and Cox2 (Scherz, 
Huisken, Sahai-Hernandez, & Stainier, 2008) are needed for proper formation of the heart’s 
endocardial cushions and valves. Due to this conservation of elastin from zebrafish to humans, 
further research of elastin’s role in zebrafish cardiovascular development can lend some insight 
into human cardiovascular diseases.  
1.6. PUBLIC HEALTH SIGNIFICANCE 
Rare diseases are defined as having a prevalence of less than 4-5/10,000 (Richter et al., 2015) or 
less than 200,000 affected individuals in the United States, as specified in a 1984 amendment to 
the Orphan Drug Act (P.L. 97-414) of 1983. Although individually uncommon, rare diseases 
collectively affect approximately 25 million people in the US or about 10 % of the population.  
Many of 5,000-8,000 rare diseases are genetic in origin, which provides a clear path to 
understanding their cause and developing treatments for them. However, the large number of 
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different diseases and the scarcity of individuals affected by each pose a substantial challenge to 
progress and represent a major unmet medical need (Medicine, 2010).  
 
Animal models are essential for understanding the developmental and physiological basis of 
disease and as tools to develop and test therapeutic approaches (Simmons, 2008). The main goal 
of my study was to establish and characterize zebrafish with mutations in the elastin genes as 
possible models for SVAS, an obstructive cardiovascular disease affecting 1 in 20,000 live births 
that causes a narrowing of the aorta and hypertension (Baldwin et al., 2013; Metcalfe et al., 2000) 
that occurs as isolated, familial condition (OMIM 185500), or as a part of a multisystem 
developmental disorder, Williams-Beuren syndrome (OMIM 194050).  
 
The mechanistic and therapeutic insights from rare diseases are often applicable to common 
disorders because of a shared underlying biological pathway (Bauer-Mehren et al., 2011) or 
similarities in clinical presentation. The association of SVAS with hypertension (Wagenseil & 
Mecham, 2012), valvular defects (Greutmann et al., 2012) and other congenital heart defects 
(CHDs) is of broader public health relevance. The Centers for Disease Control and Prevention 
report that 1 in 3 adults suffers from hypertension and costs the United States $46 billion each 
year ("High Blood Pressure Facts," 2018; Nwankwo, Yoon, Burt, & Gu, 2013). Cardiovascular 
disease accounts for about 17 million deaths per year worldwide ("Cardiovascular diseases 
(CVDs)," 2017)  and in 2014 at least 1,100 deaths each day were due to hypertension in the United 
States alone ("High Blood Pressure Facts," 2018). About 40,000 infants in the United States are 
born each year with CHDs, the leading cause of birth defect related death, and over 2 million 
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people from infants to adults had some form of a CHD in 2010. Overall hospital costs for patients 
with CHD totaled about $1.4 billion in 2004, with the average cost per patient increasing based 
on the severity of their CHD ("Data & Statistics," 2018). 
1.7. DISSERTATION AIMS 
Zebrafish have two tropoelastin genes, elna and elnb. While research has been done to sequence 
the genes in their entirety, for comparison to each other and other species (Chung et al., 2006; 
He et al., 2007), little has been published about the genetic diversity of these gene transcripts in 
zebrafish. Characterizing the genetic and transcript diversity is important since genetic diversity 
helps to explain how adapting genomes contribute to the survival of a species. In addition, the 
sequence variation in the zebrafish elastin genes critically affects the design and interpretation 
of experiments that genetically manipulate them. 
 
While extensive research has been done on the development of the cardiovascular system in 
zebrafish, elastin’s role has received less attention. Only recently, zebrafish elnb morphants and 
mutants were found to have cardiac outflow tracts populated by cardiomyocytes instead of 
smooth muscle cells observed in control fish, indicating that elnb is essential for correct cell fate 
decisions in the developing heart (Moriyama et al., 2016).  
 
The main goal of this research is to generate and characterize a set of SVAS-like mutant zebrafish 
lines. The animals will be valuable tools for the understanding and development of molecular 
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mechanisms of elastin-related disorders and targeted treatments, as the zebrafish is an excellent 
animal model for small molecule screening and chemical genetics (Murphey & Zon, 2006).  
 
Based on published knowledge, I hypothesize that elastins are essential for the development of 
specific components of the cardiovascular system, including the cardiac valves and outflow tract. 
To address this hypothesis, the developmental and physiological consequences of elastin 
mutations in an in vivo zebrafish model must be investigated. Therefore, two specific aims were 
pursued:   
Aim 1: Characterize the genetic and transcript diversity of elna and elnb in zebrafish by 
sequencing cDNA clones.  
Aim 2: Characterize elna and elnb mutants by genetic and gene expression studies, 
investigate the cardiovascular and connective tissue phenotypes of mutants using 
transgenic reporter fish, confocal and video microscopy and echocardiography. 
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2.0   METHODS 
2.1. ZEBRAFISH MAINTENANCE AND CARE 
Adult zebrafish (Danio rerio) were housed in the Zebrafish Facility of the University of Pittsburgh. 
Animal maintenance and husbandry was conducted according to the facility’s standard operating 
procedures, NIH guidelines and The Zebrafish Book (Westerfield, 2007), and a research protocol 
approved by the University of Pittsburgh Institutional Animal Care and Use Committee (IACUC) . 
To limit pain and discomfort, the FDA-approved anesthetic tricaine (ethyl 3-aminobenzate 
methylsufonate) is prepared as a 4mg/mL solution and used as a 0.16mg/mL solution in tank 
water to minimize stress in handling fish when immobilizing for injection or photographic 
procedures. Embryos were staged using published guidelines (Kimmel, Ballard, Kimmel, Ullmann, 
& Schilling, 1995) and  grown at 28.5°C in 30% Danieau solution [17mM NaCl, 2mM KCl, 0.12mM 
MgSO4, 1.8 mM Ca(NO3)2, 1.5mM HEPES]. In cases where melanin development had to be 
prevented, the embryo medium also included 0.0003% phenylthiourea (PTU). 
2.2. ZEBRAFISH LINES 
The wildtype (WT) Tü/AB* line of fish is a cross between the wildtype Tübingen and AB lines 
(Staff, 2016). These fish are from established lines maintained in the lab. For elna and elnb, 
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mutant lines were obtained from the Sanger Institute Zebrafish Mutation Project, elnasa12235, 
c.264T>A, p.Tyr88* and elnbsa24024, c.1771C>T, p.Gly591Asp. Several rounds of breeding were 
done to establish a homozygous mutant elnasa/sa and elnbsa/sa lines. (For brevity, I will use elnasa 
and elnbsa for these mutants throughout the dissertation.) Homozygous mutants (elnasa/sa) were 
outcrossed with a Tg(acta2:mCherry)ca8;Tg(myl7:eGFP)twu34 transgenic line to develop a double 
transgenic mutant line of elna fish (Raya et al., 2003; Whitesell et al., 2014). 
2.3. EXISTING TRANSCRIPT INFORMATION 
Transcript sequences of elna and elnb were downloaded from the GenBank database of elna & 
elnb and imported into CLC Main Workbench 6 to be used as reference sequences. elna reference 
sequences are NM_001080063, and XM_009291325.1 – XM_009291348.1, and elnb reference 
sequences are NM_001048064.1, NM_001048064.2, and XM_005161444.1. The XM prefix 
associated with these sequences indicate model RefSeqs that contain differences, errors, or gaps 
in the sequence either predicted or from submissions and vary from the NM curated sequences 
available. The pipelines used to create these prediction sequences are automated and 
periodically the data are refreshed, and the sequences eliminated from the database ("The NCBI 
Eukaryotic Genome Annotation Pipeline," 2018). At the time of the download, June 15, 2015, 
these were the available reference sequences. 
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2.4. RNA EXTRACTION FOR TRANSCRIPT CLONING AND QUALITY CONTROL 
Total RNA was extracted from thirty 72 hours post fertilization (hpf) WT Tü/AB* larvae from a 
single clutch obtained by group breeding of 13 adults. I used 500µL Trizol and immediate 
homogenization with a pestle homogenizer. For phase separation, 50µL of BCP was added, 
shaken manually for 15 seconds to form an emulsion, incubated on ice for 5 minutes, then 
subjected to centrifugation at 12,000xg for 10 minutes at 4oC. The aqueous phase on top was 
transferred to a Qiagen RNeasy spin column from the RNeasy Mini Kit. The rest of RNA extraction 
was conducted by following the RNeasy protocol. Final concentrations of RNA were measured 
using UV spectrophotometry. RNA integrity was verified by agarose gel electrophoresis. 
2.5. REVERSE TRANSCRIPTION AND POLYMERASE CHAIN REACTION (RT-PCR) 
Reverse transcription was conducted using the Superscript IV Reverse Transcriptase Kit 
(Invitrogen) following the manufacturer’s instructions using 1µg of RNA and random hexamers. 
PCR amplification of elna and elnb cDNA fragments was done using the Qiagen Multiplex Kit with 
HotStarTaq DNA Polymerase using primer sets (Table 29, Table 30), with a 30 second annealing 
time, 1-minute extension for amplicons up to 1 kb, 3-minute extension for amplicons over 1 kb, 
and 35 total cycles. The sizes and quality of RT-PCR products were verified by agarose gel 
electrophoresis. 
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2.6. MOLECULAR CLONING, SEQUENCING, AND SNP CONFIRMATION 
Amplicons were cloned using the pCR™II-TOPO® TA vector with the TOPO Cloning Kit (Invitrogen) 
into One Shot® TOP10 chemically competent E. coli cells and plated onto LB agarose with 
ampicillin overnight at 37oC. Following incubation, colonies were picked and incubated overnight 
in 2mL LB Broth with 100 µg/mL ampicillin. Plasmid DNA was isolated using the Monarch Plasmid 
Miniprep Kit (New England Biolabs) according to the manufacturer’s instructions. For the final 
step, the plasmids were eluted from the column using 20µL of Elution Buffer to achieve high 
concentration, which was measured by UV spectrophotometry. Plasmid clones were digested 
with EcoRI to liberate the cDNA fragments and confirm their size by agarose gel electrophoresis. 
Plasmid clones were subjected to fluorescent dideoxy cycle sequencing using primers 
complementary to the plasmid backbone and additional, regularly spaced internal primers, 
(Table 31, Table 32) against the cDNA. Operon was used as a sequencing service provider. 
Sequence traces were imported into Sequencher v5.4, were trimmed to remove low quality 
regions and aligned. Vector sequences were removed. The alignments contained complete 
bidirectional coverage of each cDNA clone with the depth of coverage ranging 2-6. Complete 
cDNA clone sequences were imported into CLC Main Workbench v6 and annotated for exon and 
variant content using sequence searching and multiple alignment functions.  
 
Exon-exon boundaries were confirmed by comparisons against cDNA and genomic reference 
sequences. Amplification primer sequences were trimmed, and sequences were exported in 
FASTA format for submission to GenBank using the BankIt web interface. The splice site scores 
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were determined using a website algorithm (Reese, 2018). Variants with existing rs numbers 
were identified through data mining on the Ensembl website. Filters were applied to narrow 
down existing variants that were similar to those found in the sequences. 
2.7. SNP CONFIRMATON IN gDNA 
Confirmation of single nucleotide polymorphisms (SNPs) found in the cDNA from embryos was 
executed using gDNA from tail-clips of the adult zebrafish parents of the clutch. gDNA was 
amplified using the Qiagen Multiplex Kit with HotStarTaq DNA Polymerase and sets of primers 
(Table 3, Table 4), with a 30 second annealing time, 30 second extension and a total of 32 total 
cycles. PCR products underwent quality control by agarose gel electrophoresis, were treated with 
exonuclease I and shrimp alkaline phosphatase using 1 μL of ExoSAP-IT (Thermo Fisher Scientific) 
in a reaction with 5 μL of PCR sample and 9 μL of water. The reaction was incubated for 40 
minutes at 37°C followed by 20 minutes at 80°C to inactivate the enzymes. Samples were then 
sent to sequence using the Operon service and analyzed with the Sequencher v5.4 software. 
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Table 3. Primers to Confirm SNPs in elna gDNA 
Primer Name Sequence 
Intron (I) or 
Exon (E) # 
zf elna I10.1s* TCAAACCTCGTGATCATCAT 10 (I) 
zf elna I10.2s* TAGCTGCCCTCCATTACACAG 10 (I) 
zf elna I14.1s* ACCATGAGTATTGTCTGCT 14 (I) 
zf elna I17.1a* AGACCAACCTATCCCAGCAA 17 (I) 
zf elna I33.1s* TTCAGCAGGGATAGCATATTC 33 (I) 
zf elna I35.1a* AGACAGCTGAAACAGAAAAG 35 (I) 
zf elna I36.1s* TCTGAGGTTTTGAGGATTGT 36 (I) 
zf elna I39.1a* ATAAAGGGACTAAGCCGAAA 39 (I) 
zf elna I40.1s* ATGTGGCAATGTTGTGTATG 40 (I) 
zf elna I45E46.1a* GAAGCTTGGCTGTGGATAGA 45 (I), 46 (E) 
zf elna I50.1s* TGAACAGCAGACAGACAGTA 50 (I) 
zf elna I51.1a* ACAACACCACCTTCATCTCCA 51 (I) 
zf elna I13.1a* TTATTGGGTGCTAAAGCTGG 13 (I) 
zf elna I35.2a* AATACTCGATTCACACTCAG 35 (I) 
zf elna I39.2a* ATAAGTTGGCGGTTCATTCC 39 (I) 
zf elna I43.1s* ACCAACGAACAGGTCACAAT 43 (I) 
zf elna I41.1a* GAAACGCACTGTTATGACAA 41 (I) 
zf elna I50.2s* AAACAGCCCAACGGGTCAAA 50 (I) 
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Table 4. Primers to Confirm SNPs in elnb gDNA 
Primer Name Sequence 
Intron (I) or 
Exon (E) # 
zf elnb I6E7.1s TGCTTAAAGGTGTGGGTGGA 6 (I), 7 (E) 
zf elnb I9E10.1a ACCATAGCCACCTAAAAACA 9 (I), 10 (E) 
zf elnb I9E10.2a ATAAATACCTCCTGGCCCAC 9 (I), 10 (E) 
zf elnb E31I31.1s ATGGTACGGGGAAATGAAAC 13 (I) 
zf elnb E33.1a TTTAAGGCTTTTGCTCCAC 33 (I) 
zf elnb I33.1a AAAGCTGCAGAACAAAACAC 33 (I) 
zf elnb E40.1s TGATTGGCAGCCCTGATGG 40 (I) 
zf elnb I40.1s ACCCAATACCTAACCACAAC 40 (I) 
zf elnb I43.1a AAAATGCTAAGAGTCACGAG 43 (I) 
zf elnb E47.2a AATCCTGTGCCTGCAGCTC 47 (E) 
zf elnb E47.3a CAACACCTCCAACTCCAAGA 47 (E) 
zf elnb I33.2s GACATTGTGTTTTGTTCTGC 33 (I) 
zf elnb I34.1a AGTTGATCAGACTACAGCAT 34 (I) 
zf elnb I50.1a ACCCATGTTAACCCAAAACT 50 (I) 
zf elnb I50.2a GAAAATCCAAAAAGAGCCAC 50 (I) 
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2.8. GENOTYPING OF ZEBRAFISH BY dCAPS 
Confirmation of the mutations (elnasa12235, c.264T>A, p.Tyr88*) and (elnbsa24024, c.1771C>T, 
p.Gly591Asp) in mutants obtained from the Sanger Institute Zebrafish Mutation Project was done 
by genotyping using the derived cleaved amplified polymorphic sequences (dCAPS) method 
(Neff, Neff, Chory, & Pepper, 1998). The technique requires the creation of primers that 
introduce a polymorphism based on the target mutation and induce a restriction endonuclease 
recognition site in either the mutant or WT DNA sequence through base mismatch. Primers 
(Table 5) were designed using a web-based primer design software to detect the mutations (Neff, 
Turk, & Kalishman, 2002).  Genotyping was performed on whole embryos and adult tail-clip 
biopsies. Genomic DNA (gDNA) was isolated using the DNeasy Blood and Tissue Kit (QIAGEN). 
10ng of gDNA was used for each PCR amplification reaction.  The amplifications for elna and elnb 
were digested at 37oC for 90 minutes, using DdeI and Hpy188I respectively, and run on 3% 
Metaphor agarose gel.  DNA sequencing was done with the service provider Operon. 
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Table 5. dCAPS Primers for Genotyping elna and elnb 
 
For both elna and elnb, the C mismatch (green and underlined) changed an A base in the original sequence. 
The enzyme cutting site (indicated by ^ in the recognition sequence) targeted the mutant alleles (elna: T>A, 
elnb: C>T). If the mutant allele was present, the enzyme would cut.   
2.9. RNA ISOLATION TO STUDY THE EXPRESSION OF MUTATIONS 
Total RNA was extracted from adult zebrafish hearts, swim bladders, tail-clips and 10-30 embryos 
using the same method as described in Section 2.4. The number of embryos was dependent on 
their age. Reverse transcription was performed as described in Section 2.5. PCR was done using 
the Qiagen Multiplex Kit with HotStarTaq DNA Polymerase, primers (Table 6) with a 30 second 
annealing time, 30 second extension and a total of 35 total cycles. The sizes and quality of RT-
PCR products were verified by agarose gel electrophoresis. PCR product cleanup and sequencing 
were performed as described in Section 2.7. 
  
Gene 
Amp 
Amp 
Size 
(bp) 
Primer Name Exon Sequence Enzyme 
Enzyme 
Recognition 
Sequence 
elna 276 
zf elna 
I4E5s*DdeI 
intron 4 –  
exon 5 TATCTCTCTGGCTGTAGGTGGCTA DdeI 5’…C^TNAG…3’ 
zf elna E6.1a* 6 ACCTCCAGGCAGAACTCCTC 
elnb 285 
zf elnb E17.1s 
Hpy188I 17 TCTCAGGCTAAAGCTGCCAAGTCTG Hpy188I 5’…TCN^GA…3’ 
zf elnb E18.3a 18 AATGCCTCCAACACCTGGTA 
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Table 6. RT- PCR primers to investigate the expression of mutations 
 
Gene 
Amp 
Amp 
Size 
(bp) 
Primer Name Exon Sequence 
elna 787 
zf elna KE1.1s 1 TTGCTCCTTCTCGGATTCTT 
zf elna E9.1a 13 TGGGAGATTTGAGGGGGT 
elnb 285 
zf elnb E17.1s 
Hpy188I 17 TCTCAGGCTAAAGCTGCCAAGTCTG 
zf elnb E18.3a 18 AATGCCTCCAACACCTGGTA 
 
2.10. EMBRYO HEART RATE MEASUREMENT 
Embryos were kept in individual wells of 24-well plates, removed from the incubator and brought 
to room temperature to equalize environmental conditions of all embryos. Embryos at 5 days 
post fertilization (dpf) and 7 dpf were placed into a drop of water to eliminate the need for 
tricaine and keep them in place for observation using a stereomicroscope. Heart rates were 
measured by counting heart beats for 1 minute through direct observation.  
2.11. ADULT ORGAN EXTRACTION, WHOLE-MOUNT HART’S ELASTIN STAINING 
Adult zebrafish were euthanized using 0.64mg/mL tricaine.  Dissection and extraction of the adult 
heart was done using published guidelines (Gupta & Mullins, 2010). The hearts were fixed in 10% 
buffered formalin (Protocol, Fisher Scientific) and stored at 4°C until ready for sectioning. The 
heart tissue was embedded in paraffin wax and sectioned by the Tissue and Research Pathology 
Services of the University of Pittsburgh Cancer Institute and mounted onto glass slides. A 
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modified version of the Hart’s Elastin Staining Protocol was used to stain the hearts for elastin (R. 
Mecham, 2018). Slides were first deparaffinized by soaking in Histo-clear (National Diagnostics) 
for 15 minutes, followed by rehydration in an ethanol series (100%, 95%, 80%, 70%, 50%, 30%, 
tap water) with 10 dips per solution. The slides then were immersed in 0.25% potassium 
permanganate solution for 5 minutes, rinsed by dipping 10 times in tap water, incubated in 5% 
oxalic acid solution for 5 minutes, and rinsed again by dipping 10 times in tap water. Slides were 
stained in resorcin-fuchsin working solution (PolyScientific) for 2 hours and rinsed in tap water 
by dipping 30 times, with a change of water every 10 dips, followed by a soak for 5 minutes. Slides 
were counterstained in tartrazine working solution (2% tartrazine, 2% acetic acid) for 2 hours, 
dipped once in tap water, and dehydrated in the same ethanol series in reverse order with 1 dip 
per concentration. The slides were soaked in histoclear for 2 minutes and mounted under 
coverslips using Permount. Viewing and imaging of slides was done using a Leica DM5000 
fluorescent microscope using transmitted light settings.  
2.12. WHOLE-MOUNT IMMUNOSTAINING 
Whole embryos were fixed in 4% paraformaldehyde (PFA) at 4°C overnight. After fixation, the 
embryos were washed 2 times for 5 min each with 0.1% Triton X-100 (TX-100) in 1X phosphate-
buffered saline (PBS), followed by an incubation in PBS containing 0.5% TX-100 at room 
temperature for one hour. After the incubation, the embryos were blocked in blocking buffer 
containing 1% dimethyl sulfoxide (DMSO), 1% TX-100, 0.2% bovine serum albumin (BSA) and 5% 
goat serum prepared in PBS for 3 hours. Embryos were then incubated overnight at 4°C in a 1:250 
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dilution of elna primary antibody prepared in blocking buffer. The following day, the embryos 
were washed in 1 mL of blocking buffer for 5 minutes, then washed 4 times with 500 μL of 0.1% 
TX-100 in PBS for 30 minutes each wash. Embryos were then blocked in 500 μL of blocking buffer 
for 1 hour, then stained with secondary antibody Alexa Fluor 568 anti-rabbit IgG (Thermo Fisher 
Scientific, A-11011) in a 1:250 dilution for 3 hours. Staining was followed by 4 washes of 5 minutes 
each in 0.1% TX-100 in PBS, then left overnight at 4°C in 1X PBS. Imaging of embryos was done 
using an Olympus BX51 microscope and DP71 camera. 
2.13. CONFOCAL IMAGING AND VIDEO MICROSCOPY 
Homozygous mutants (elnasa/sa) were outcrossed with a Tg(acta2:mCherry)ca8;Tg(myl7:eGFP)twu34 
transgenic line to obtain elnasa/+;Tg(acta2:mCherry)ca8;Tg(myl7:eGFP)twu34 adults, which were in-
crossed to obtain homozygous mutant double transgenic fish. Both wildtype 
Tg(acta2:mCherry;myl7:eGFP) and elnasa/sa Tg(acta2:mCherry;myl7:eGFP) embryos were grown 
in 30% Danieau solution [17mM NaCl, 2mM KCl, 0.12mM MgSO4, 1.8 mM Ca(NO3)2, 1.5mM 
HEPES] containing 0.0003% phenylthiourea (PTU) up to 7 dpf. Larvae were mounted ventral side 
down on 35mm glass bottom plates (MatTek, P35G-0.170-14-C) using 2% low-melt agarose with 
0.16mg/mL tricaine. Imaging was done using a Nikon A1 Confocal microscope at the Center for 
Biologic Imaging (CBI) at the University of Pittsburgh. Maximum projection images were then 
analyzed, and measurements taken using the Nikon NIS-Elements software. Wildtype Tü/AB* and 
elnasa/sa fish were also grown to 7 dpf in the same manner and mounted using the same technique 
for taking videos of the hearts using a differential interference contrast (DIC) microscope, the 
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Nikon Ti Live Cell microscope and Photometrics PRIME 95B camera, and the Nikon NIS-Elements 
software for analysis. 
2.14. ECHOCARDIOGRAPHY 
Working with one zebrafish at a time, an adult zebrafish was first placed into Tricaine at a 
concentration of 0.12mg/mL made in system water to induce anesthesia for a length of 2 
minutes. Fish were monitored to assure respiration did not cease. The fish was then transferred 
into a separate container containing Tricaine at a concentration of 0.096mg/mL used to maintain 
anesthesia for the length of the echocardiography scanning. Fish were held in the ventral position 
using a sponge immersed in a container with 0.096mg/mL maintenance Tricaine. Concentration 
of Tricaine for anesthesia induction and maintenance may need to be adjusted for each line. 
 
Echocardiography imaging was done using a Fujifilm Visualsonics Vevo 2100 Micro-ultrasound 
animal imaging system. The probe was placed on the ventral side of the immersed fish to obtain 
blood flow images using the system’s color Doppler modes. Once images were obtained, the 
zebrafish was placed into system water without Tricaine.  
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3.0    RESULTS 
3.1    TRANSCRIPT DIVERSITY IN ZEBRAFISH ELASTIN GENES 
To assess transcript diversity in elna and elnb, cDNA clones were generated from thirty 72 hours 
post fertilization (hpf) wildtype Tü/AB* larvae. The RNA was subjected to reverse transcription 
using random hexamers and to PCR amplification using sets of primers (Table 29, Table 30) 
designed to cover elna and elnb transcripts in 6 and 8 overlapping fragments, respectively. For 
each cDNA fragment, at least 5 clones were sequenced completely on both strands using primers 
complementary to the plasmid backbone and additional, regularly spaced internal primers (Table 
31, Table 32) against the cDNA. A total of 46 elna and 44 elnb clones were sequenced.  
 
I uncovered substantial variation in cDNA sequences from both genes (Table 7). The possible 
sources of these sequence variants include genetic variation, alternative splicing, and reverse 
transcriptase or PCR errors. Assignment of the observed sequence variation to these causes is 
not straightforward and required making the following assumptions. Single nucleotide variants 
and insertion deletion variation with breakpoints within exons were assumed to be genetic, 
whereas insertion-deletion variants with breakpoints at exon-exon junctions or at cryptic splice 
sites were assumed to be alternative splicing variants. I considered variants observed in more 
than one clone to less likely be the result of PCR errors.  
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The majority of variants were single nucleotide variants (SNVs) with a total of 79 SNVs in 
elna and 89 in elnb. In addition, there were numerous length variants, transcript and 
genetic diversity represented by alternative splicing events and in-del variants. All SNPs 
observed were cross-checked with the transcript sequences obtained from ensemble.org 
and the available variant table.  11 out of 79 variants in elna (9 silent and 2 missense), and 
2 out of 89 variants in elnb (both silent) were found to already have a corresponding 
accession number (rs #). The majority of SNVs for these genes with rs #s in the current 
dbSNP database are intronic. I found more silent SNVs in elna than elnb (51 and 36 
respectively), but elnb had a larger number of missense mutations than elna (41 and 19 
respectively). The full list of variations (Table 8 to Table 17, Table 19, Table 20) in elna and 
elnb that were found in the cDNA sequences are visualized in Figure 8 and Figure 9. 
 
  
Table 7. Summary of Variations in elna and elnb 
Alternative Splicing: elna – 5 (2), elnb – 3 (2) 
SNV (splice):  elna – 1 (0) 
SNV (silent):  elna – 52 (29), elnb – 36 (10) 
SNV (missense):  elna – 19 (6), elnb – 41 (13) 
SNV (nonsense): elnb – 2 (0) 
In-del variants:  elna – 9 (3), elnb – 10 (4)  
Note: the number of variants found in more than one 
clone is shown in brackets 
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Table 8. Silent SNVs Identified in Exons 2-39 of elna cDNA 
Variant 
Name Type Type Detail Exon # rs # # of Clones 
c.90A>G SNV Silent 2  2 
c.105A>G SNV Silent 2  3 
c.201A>G SNV Silent 4  1 
c.267G>A SNV Silent 5  1 
c.645A>G SNV Silent 10  1 
c.657A>G SNV Silent 11  1 
c.660A>G SNV Silent 11 rs503122350 1 
c.684G>A SNV Silent 11 rs508262317 4 
c.717G>A SNV Silent 12  3 
c.753G>A SNV Silent 13  1 
c.798C>T SNV Silent 13 rs505315146 1 
c.819T>C SNV Silent 14  1 
c.936G>A SNV Silent 15  5 
c.999T>C SNV Silent 17 rs509607459 3 
c.1008A>G SNV Silent 17  3 
c.1041T>C SNV Silent 17  3 
c.1287G>C SNV Silent 21  1 
c.1314C>T SNV Silent 31  1 
c.1647T>C SNV Silent 25  1 
c.1800T>G SNV Silent 27  1 
c.2010A>G SNV Silent 29  1 
c.2043A>G SNV Silent 30  1 
c.2058T>C SNV Silent 31  1 
c.2094T>C SNV Silent 31  1 
c.2262T>C SNV Silent 33  2 
c.2430T>C SNV Silent 36  1 
c.2481T>C SNV Silent 37  1 
c.2505G>T SNV Silent 38 rs40920497 11 
c.2571T>C SNV Silent 39  10 
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Table 9. Silent SNVs Identified in Exons 41-55 of elna cDNA 
Variant 
Name Type Type Detail Exon # rs # # of Clones 
c.2640A>T SNV Silent 41  10 
c.2643A>G SNV Silent 41  10 
c.2646T>C SNV Silent 41  1 
c.2655A>G SNV Silent 41  10 
c.2661A>T SNV Silent 41  3 
c.2667G>A SNV Silent 41  10 
c.2673A>T SNV Silent 41  3 
c.2676A>T SNV Silent 41  3 
c.2679A>G SNV Silent 41  3 
c.2682T>A SNV Silent 41  10 
c.2685T>A SNV Silent 41  16 
c.2688T>A SNV Silent 41  6 
c.2814T>C SNV Silent 43  2 
c.2847T>C SNV Silent 44  1 
c.2862G>T SNV Silent 45 rs41232150 17 
c.2892T>G SNV Silent 45 rs41056348 5 
c.2898C>T SNV Silent 45 rs41239681 5 
c.3219G>C SNV Silent 50 rs40973069 6 
c.3252T>G SNV Silent 51  6 
c.3255C>T SNV Silent 51  2 
c.3290A>G SNV Silent 52  1 
c.3363A>T SNV Silent 54  1 
c.3435A>G SNV Silent 55  1 
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Table 10. Silent SNVs Identified in Exons 8-39 of elnb cDNA 
Variant 
Name Type Type Detail Exon # rs # # of Clones 
c.678T>C SNV Silent 8  1 
c.726C>T SNV Silent 8  3 
c.747C>A SNV Silent 8  3 
c.891T>C SNV Silent 8  3 
c.1074G>A SNV Silent 9  3 
c.1392T>C SNV Silent 12  2 
c.2394A>G SNV Silent 22  1 
c.2514T>A SNV Silent 22  1 
c.2538G>A SNV Silent 23  1 
c.2583T>A SNV Silent 24  1 
c.2589T>C SNV Silent 24  1 
c.2595A>T SNV Silent 24  1 
c.2598T>C SNV Silent 24  1 
c.2692C>T SNV Silent 24  1 
c.3133T>C SNV Silent 26  1 
c.3168G>T SNV Silent 26  1 
c.3222A>G SNV Silent 27  1 
c.3304T>C SNV Silent 28 rs501804407 1 
c.3306A>G SNV Silent 28  2 
c.3423A>G SNV Silent 28  1 
c.3471T>C SNV Silent 30  1 
c.3531T>G SNV Silent 30  1 
c.3570A>G SNV Silent 30  1 
c.3717A>G SNV Silent 31  1 
c.3738T>C SNV Silent 32  1 
c.3909G>T SNV Silent 32 rs511964010 2 
c.3924A>T SNV Silent 32  2 
c.3933G>A SNV Silent 32  2 
c.4422A>G SNV Silent 39  2 
c.4425T>C SNV Silent 39  1 
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Table 11. Silent SNVs Identified in Exons 46-56 of elnb cDNA 
Variant 
Name Type Type Detail Exon # rs # # of Clones 
c.4743A>G SNV Silent 46  1 
c.4872A>G SNV Silent 46  1 
c.4965T>C SNV Silent 46  1 
c.5139T>C SNV Silent 46  1 
c.5391C>A SNV Silent 49  1 
c.6003A>G SNV Silent 56  1 
 
 
 
 
 
Table 12. Missense SNVs Identified in elna cDNA 
Variant Name Type Type Detail Exon # rs # # of Clones 
c.10A>G p.Arg3Gly SNV Missense 1  1 
c.627A>C p.Gln209His SNV Missense 10  1 
c.664G>A p.Val222Ile SNV Missense 11  1 
c.1037T>C p.Val346Asp SNV Missense 17  3 
c.1693A>G p.Ile565Val SNV Missense 25  1 
c.1876A>G p.Thr626Ala SNV Missense 27  3 
c.1973T>C p.Ile658Thr SNV Missense 29  1 
c.2168G>A p.Gly723Glu SNV Missense 31  1 
c.2341C>T p.Leu781Phe SNV Missense 34  4 
c.2587A>G p.Thr863Ala SNV Missense 39  1 
c.2683G>A p.Gly895Ser SNV Missense 41  1 
c.2735T>C p.Val912Ala SNV Missense 41  1 
c.2810G>A p.Gly937Ala SNV Missense 41  1 
c.2833G>A p.Gly945Ser SNV Missense 41  10 
c.2876C>T p.Thr959Ile SNV Missense 41 rs40859418 5 
c.3007C>T p.Leu1003Phe SNV Missense 41  1 
c.3214G>A p.Gly1072Arg SNV Missense 41  1 
c.3527A>G p.Glu1086Gly SNV Missense 41  1 
c.2876C>T p.Thr959Ile SNV Missense 45 rs40859418 5 
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Table 13. Missense SNVs Identified in Exons 2-28 of elnb cDNA 
Variant Name Type Type Detail Exon # rs # Clone # 
c.235A>G p.Thr79Ala SNV Missense 2  1 
c.376G>A p.Gly126Ser SNV Missense 3  1 
c.580G>A p.Thr194Ala SNV Missense 5  1 
c.686T>C p.Thr229Ile SNV Missense 8  3 
c.709G>A p.Val237Ile SNV Missense 8  3 
c.1232C>T p.Ala411Val SNV Missense 11  2 
c.1294A>G p.Thr432Ala SNV Missense 11  1 
c.1375C>T p.Pro459Ser SNV Missense 12  2 
c.1498C>T p.Pro500Ser SNV Missense 13  1 
c.1553A>G p.Gln518Arg SNV Missense 14  1 
c.1571A>G p.Gln524Arg SNV Missense 15  1 
c.1624G>A p.Val542Met SNV Missense 16  1 
c.2077G>A p.Gly693Arg SNV Missense 20  2 
c.2179T>C p.Ser727Pro SNV Missense 20  2 
c.2230G>T p.Val744Leu SNV Missense 20  3 
c.2333G>A p.Gly778Asp SNV Missense 22  2 
c.2507G>A p.Gly836Glu SNV Missense 22  1 
c.2510T>C p.Ile837Thr SNV Missense 22  1 
c.2534C>T p.Thr845Ile SNV Missense 22  2 
c.2547C>G p.Asp849Glu SNV Missense 23  1 
c.2617A>G p.Thr873Ala SNV Missense 24  1 
c.2642G>T p.Gly881Val SNV Missense 24  1 
c.2830A>G p.Gly944Ala SNV Missense 24  1 
c.3181C>A p.Leu1061Ile SNV Missense 26  1 
c.3274G>A p.Gly1092Ser SNV Missense 28  1 
c.3427G>A p.Gly1143Arg SNV Missense 28  1 
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Table 14. Missense SNVs Identified in Exons 30-55 of elnb cDNA 
Variant Name Type Type Detail Exon # rs # # of Clones 
c.3551T>C, p.Ile1184Thr SNV Missense 30  1 
c.3604A>G, p.Ile1202Val SNV Missense 30  1 
c.3625C>T, p.Pro1209Ser SNV Missense 30  1 
c.3635T>C, p.Val1212Ala SNV Missense 30  1 
c.3653G>A, p.G1218E SNV Missense 30  1 
c.3725T>C, p.Ile1242Thr SNV Missense 32  2 
c.4175C>T, p.Pro1392Leu SNV Missense 34  1 
c.4354G>A, p.Gly1452Ser SNV Missense 38  10 
c.4943T>C, p.Val1648Ala SNV Missense 46  1 
c.5324A>G, p.Gln1775Arg SNV Missense 47  1 
c.5326A>G, p.Lys1776Glu SNV Missense 47  1 
c.5342A>G, p.Tyr1781Cys SNV Missense 48  2 
c.5533G>A, p.Gly1845Ser SNV Missense 50  4 
c.5762G>A, p.Gly1921Asp SNV Missense 52  1 
c.6007T>C, p.Phe2003Leu SNV Missense 55  1 
 
 
 
Table 15. Nonsense SNVs Variants Identified in elnb cDNA 
Variant Name Type Type Detail Exon # rs # Clone # 
c.3463A>T, p.K1155* SNV Nonsense 29  1 
c.4153C>T, p.Gln1385* SNV Nonsense 34  1 
  
 
 
 56 
Table 16. Indel Variants Identified in elna cDNA 
Variant Name Type Type Detail Exon # rs # # of Clones 
c.107_109del Deletion In-frame 2  1 
c.330_345del Deletion +2 frameshift Part 5 to part 6 
 1 
c.1115_2188del Deletion In-frame Part 18 to 31  1 
c.1418_1636del Deletion In-frame Part 23 to      part 25 
 1 
c.1453_2085del Deletion In-frame Part 23 to       part 31 
 1 
c.1595_1636del Deletion In-frame 25  2 
c.1808_1828del Deletion In-frame 27  3 
c.434...468dup Duplication +2 frameshift Part 6 to 7  1 
c.1037_1078dup Duplication In-frame 17  4 
 
 
Table 17. Indel Variants Identified in elnb cDNA 
Variant Name Type Type Detail Exon # rs # # of Clones 
c.2071_2250del Deletion In-frame 20  1 
c.2198_2821del Deletion In frame Part 20 to part 24 
 1 
c.2629_3291del Deletion In-frame Part 24 to part 28 
 1 
c.2635_3042del Deletion In-frame Part 24 to part 26 
 1 
c.2704_3318del Deletion In-frame Part 24 to part 28 
 1 
c.2861_3556del Deletion In-frame Part 24 to part 30 
 1 
c.3902_3931del Deletion In-frame 32  5 
c.4872_5018del Deletion In-frame 46  3 
c.5095_5136del Deletion In-frame 46  2 
c.5538_5561del Deletion In frame 50  4 
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Figure 8. Graphical Representation of Transcript and Genetic Variants in elna  
Each exon of elna is displayed as a column of cells. The rows show transcripts annotated in Ensembl (X1-X24, 
top), or individual cDNA clones sequenced in this study (bottom). Each group of clones is surrounded by a 
black outline. A large number of SNVs are observed from exons 38-51. Pale green – the exon’s full sequence 
is present and matches the reference sequence. 
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Figure 9. Graphical Representation of Transcript and Genetic Variants in elnb   
Each exon of elna is displayed as a column of cells. The rows show transcripts annotated in Ensembl (101, 201, 
202, top), or individual cDNA clones sequenced in this study (bottom). Each group of clones is surrounded by a 
black outline. Pale green – the exon’s full sequence is present and matches the reference sequence. 
 
Upon annotating the sequences in CLC Main, I noticed a non-random distribution (clustering) of 
SNVs throughout the eln genes (Figure 8, Figure 9).  In elna, 3 exons had 4 or more SNVs (exon 11 
- 4, exon 41 - 13, and exon 45 - 4), and elnb had 2 exons with 5 SNVs each (exon 28 – 5, exon 46 
– 5). Exon 41 had the largest cluster (Figure 10) consisting of 13 SNVs (1 missense and 12 silent). 
Because I sequenced cDNA clones, it was possible to assign SNVs to haplotypes. Assuming 2 
parents for the clutch I would expect to find a minimum or 2 and a maximum of 4 haplotypes. 
For each cluster, there were more than 2 haplotypes, with the number of haplotypes ranging 
from 3 to 6 (Table 18). The finding of more than 4 haplotypes suggests that there were more than 
2 parents of the clutch used to isolate RNA. Indeed, I used a group breeding of 13 adults to obtain 
the embryos for this experiment. An alternative explanation, supported by the observation of 16 
haplotypes marked by a single SNV, is that some of the SNVs represent PCR errors.  
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Figure 10. A cluster of 13 SNVs in exon 41 of elna 
This is an example of how SNVs have shown a tendency to cluster in portions of the cDNA.  
 
 
Table 18. Clustering and Haplotypes in elna and elnb 
Gene Exon # of SNVs # and Type of SNV Haplotype # 
elna 
11 4 Silent – 3 Missense - 1 4 
41 13 Silent – 12 Missense – 1 3 
45 4 Silent – 3 Missense – 1 3 
elnb 
28 5 Silent – 3 Missense – 2 5 
46 7 
Silent – 4 
Missense – 1 
Deletions - 2 
6 
 
 
Splice site scores for SNVs located close to exon-exon boundaries and for sites of possible 
alternative 5’ or 3’ splice site use were determined using a website algorithm. The correlation 
coefficient cut off identifies real splice sites with 5-9% false negative, and 5% false positive rates. 
The closer the score is to 1, the more likely it is to be a real splice site. For example, the splice site 
variant, changing the last nucleotide of exon 3 in elna c.196G>Tp.A66S, returned a Wildtype Score 
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of 0.98 and a Mutant Score of 0.18., indicating that this variant is likely to inactivate the splice 
site.  Predicted exon skipping events could not be interrogated this way, as they involve the use 
of existing splice consensus sequences. I found 2 SNVs with substantial effect on the 
corresponding splice site scores, a new exon between exons 46 and 47, one instance of an 
alternative 3’ and another of an alternative 5’ splice site use and 3 exon skipping events in elna 
(Table 19). The newly discovered exon also has a high splice site score and encodes an overall 
hydrophobic sequence (Figure 11) with only a single lysine and glutamic acid. The amino acid 
sequence of this domain is similar to other hybrid hydrophobic/crosslink domains encoded by 
exons 45, 49 and 51, but one of the usual 2 lysines is replaced by a glutamic acid, which is very 
rare in elastin sequences. In elnb, only one alternative 5’ splice site and 2 exon skip events were 
noted (Table 20).  
 
Table 19. Annotated SNV Splice Sites and Splice Variants Identified in elna cDNA 
Variant Name Type Type Detail Exon # Splice Score # of Clones 
c.196G>Tp.A66S SNV Splice site 3 WT:  Score 0.98  GCAGgtga                                            Var:  Score 0.18  GCATgtga   1 
c.431_445del Splice Alt splice 5' 6 WT:  Score 0.01  GGAGgtgg                                            Var:  Score 0.08  GGAGgtgc                             1 
c.709_710insCTGCAG Splice Alt splice 3' 12 WT:  Score 0.25  TCAGgtgg                                             Var:  Score 0.88  ctgcagGTGG                                           10 
c.1883_1927del Splice Exon skip 28  3 
c.2639_2731del Splice Exon skip 41 & 42  1 
c.2825_2857del Splice Exon skip 44  1 
g.46522_46563  New Exon Between 46 & 47 
Score 0.95  gcagGACC   
Score 0.84  CCCAgtaa   1 
Exons and introns in the splice junction sequences are shown in capital and lower case type, respectively. 
Clone # indicates the number of clones that displayed variant upon sequencing.  
 
 
 
 
 
 
 61 
 
 
 
Figure 11. A Schematic Representation of the Domain Context and Sequence Features of a 
New Exon in elna 
Exons 41 through 52 are shown. Note that some exons (45, 46, 49 and 51) have both hydrophobic 
and crosslink sequences. The newly discovered exon (X) has high-scoring splice sites and encodes 
an overall hydrophobic sequence with a single lysine (K, blue) and glutamic acid (E, red).  
 
 
 
 
 
 
 
 
Table 20. Annotated SNV Splice Sites and Splice Variants Identified in elnb cDNA 
Variant Name Type Type Detail Exon # rs# # of Clones 
c.5519_5599del Splice Alt splice 5' 50 WT: Score 0.25  GGTGgtaa Var: Score: 0.25  CCAGgtgg 2 
c.2537_3199del Splice Exon skip 23 to 26  1 
c.4541_4567del Splice Exon skip 42  3 
Capital letters in the Splice Score sequence indicate EXON/intron boundary. Clone # indicates the number of 
clones that displayed variant upon sequencing.  
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Once all sequences were analyzed and annotated, the amplification primer sequences were 
trimmed, and sequences were exported in FASTA format and submitted to GenBank using the 
BankIt web interface (Table 33). 
 
For further confirmation, 30 SNVs were examined in gDNA isolated from tail clips in 5 of the 13 
possible parents that were bred to produce the embryos used to obtain the mRNA. I considered 
a variant confirmed if it was either found to be polymorphic in gDNA or monomorphic for the 
minor (non-reference) allele. Of the 30 mutations, 8 of them were not reproduced in gDNA. Three 
silent SNVs in the SNV cluster in elna’s exon 41 were not reproduced. The nonsense variant found 
in elnb cDNA was not reproduced in gDNA, and only 1 of 2 missense variants was reproduced 
(Table 21). 
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Table 21.  Genomic DNA Confirmation of SNVs in elna & elnb 
Exon SNV Name Type Type Detail 
cDNA  
# of clones 
gDNA  
# of clones              
 (AA, Aa, aa)* 
elna 
34 c.2341C>Tp.Leu781Phe SNV missense 4 of 9 0, 4, 1 
41 
c.2640A>T SNV silent 10 of 21 0, 0, 5 
c.2643A>G SNV silent 10 of 21 0, 0, 5 
c.2646T>C SNV silent 1 of 21 5, 0, 0 
c.2655A>G SNV silent 10 of 21 0, 0, 5 
c.2661A>T SNV silent 3 of 21 3, 2, 0 
c.2667G>A SNV silent 10 of 21 0, 0, 5 
c.2673A>T SNV silent 3 of 21 2, 3, 0 
c.2676A>T SNV silent 3 of 21 2, 3, 0 
c.2679A>G SNV silent  3 of 21 2, 3, 0 
c.2682T>A SNV silent 10 of 21 5, 0, 0 
c.2685T>A SNV silent 16 of 21 5, 0, 0 
c.2688T>A SNV silent 6 of 21 0, 0, 5 
c.2683G>Ap.Gly895Ser SNV missense 1 of 21 0, 0, 5 
44 c.2833G>Ap.Gly945Ser 
SNV missense 10 of 21 0, 5, 0 
c.2847T>C SNV silent 1 of 21 5, 0, 0 
45 
c.2862G>T SNV silent 17 of 21 0, 1, 4 
c.2876C>Tp.Thr959Ile SNV missense 5 of 21 0, 4, 1 
c.2892T>G SNV silent 5 of 21 0, 4, 1 
c.2898C>T SNV silent 5 of 21 0, 4, 1 
51 c.3252T>G 
SNV silent 6 of 7 2, 2, 1 
c.3255C>T SNV silent 2 of 7 5, 0, 0 
elnb 
29 c.3463A>Tp.K1155* SNV nonsense 2 of 13 5, 0, 0 
32 
c.3725T>Cp.Ile1242Thr SNV missense 2 of 5 5, 0, 0 
c.3738T>C SNV silent 1 of 5 5, 0, 0 
c.3909G>T    SNV silent 2 of 5 1, 2, 2 
c.3924A>T SNV silent 2 of 5 1, 2, 2 
c.3933G>A SNV silent 2 of 5 1, 2, 2 
c.3902_3931del Deletion   5 of 5 5, 0, 0 
38 c.4354G>Ap.Gly1452Ser SNV missense 10 of 10 0, 0, 5 
       *  A: major or reference allele, a: minor, derived or new allele. Variants not reproduced by genomic DNA 
sequencing are shaded grey. 
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This leads one to question the validity of the other SNVs found in cDNA. According to studies on 
PCR induced errors, base substitution errors and other false mutations can be induced via the 
PCR amplification process and make identifying rare genetic variations a challenge (Kebschull & 
Zador, 2015; Potapov & Ong, 2017). Otherwise one must consider PCR reaction conditions’ 
influence on fidelity and the primers used. Precautions were taken to assure that primers were 
unique to a specific sequence, but both elna and elnb have highly repetitive sequences that could 
lead to primers annealing to partially homologous complementary strands. As is seen in elna 
(Table 22), where even exons 20 to 30 are the same or differ by only a single base. 
 
In addition to PCR errors, the discrepancy between the cDNA and gDNA sequences could also be 
a result of allele dropout in gDNA amplicons, in which one allele is preferentially amplified so that 
at heterozygous loci the other allele is underrepresented or missing (Hahn, Garvin, Di Naro, & 
Holzgreve, 1998). Furthermore, genotyping variants in a subset of the breeding parents could 
Exon 20 gtgctggtgcactctcccccgctcaggcaaaagctgctaaatatg 
Exon 22 gtgctggtgcactctcccccgctcaggcaaaagctgctaaatatg 
Exon 24 gtgctggtgcactctcccccgctcaggcaaaagctgctaaatatg 
Exon 26 gtgctggtgcactctcccccgctcaggcaaaagctgctaaatatg 
Exon 28 gtgctggtgcactctcccctgctcaggcaaaagctgctaaatatg 
Exon 30 gtgctggtgcactctcccctgctcaggcaaaagctgctaaatatg 
 
The elastin genes have repetitive sequence throughout the genome. 
These sequences are from elna and are an example of how entire exons 
share the same sequence. The t bases in red found in exons 28 and 30 
are the only difference between those exons and the other three. 
Table 22. Whole Exons with Same Sequence 
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also explain not being able to reproduce all mutations in gDNA. The unreproducible mutations 
may have come from un-sequenced parents. Sequencing the other parental gDNA for the 
mutations could eliminate this as a concern, but because of cost and time considerations we 
decided against further sequencing. 
3.2 VALIDATION OF elna MUTANT (elnasa12235, c.264T>A, p.Tyr88*) 
To investigate the role of elna in zebrafish development, I obtained F0 elnasa/+ female (♀) mutants 
(elnasa12235, c.264T>A, p.Tyr88*) from the Sanger Institute Zebrafish Mutation Project. This 
nonsense mutation, located in exon 5, was confirmed by DNA sequencing of gDNA isolated from 
tail biopsies of F0 and F1 fish (Figure 12).  A genotyping assay was developed using the dCAPS 
method (Figure 13), which generates a restriction enzyme site.  F0 females were first out-crossed 
to Tü/AB* WT males. The resulting F1 generation was in-crossed (elnasa/+ ♂ x elnasa/+ ♀) and 341 
out of 1,001 embryos survived to adulthood (3 months). Genotyping of the 341 adults exhibited 
a distribution of Mendelian frequencies: elnasa/+ – 183 (54%), elnasa/sa – 80 (23%), elna+/+ – 78 
(23%) at 3 months of age., indicating that this mutation was compatible with survival to 
adulthood.  A series of F1 in-crosses established an elnasa/sa colony. 
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Figure 13. Genotyping of elna using dCAPS    
The assay allows for easy identification of the genotype by single or double bands. A 
wildtype (WT - yellow) will have a single band at 276bp (top band, not cleaved by DdeI), a 
heterozygous (Het - orange) mutant have 2 bands at 276bp and 254bp, and homozygous 
(Homo - blue) mutants have a single band (bottom) at 254bp (cleaved by DdeI). There are 
12 WT, 8 Het and 2 Homo. L- 1kb ladder 
 
 
Figure 12. Sequencing of the elna wildtype and mutant alleles in gDNA from adult tail biopsy 
 
Tail biopsies were taken at 3 months of age. The peaks of the mutant allele (A - green) and wildtype 
allele (T - red) are of close to equal height in the heterozygous fish. 
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3.3    STAGE-SPECIFIC DEGRADATION OF MUTANT RNA BY NONSENSE-MEDIATED DECAY 
To determine if the mutation (c.264T>A, p.Tyr88*) destabilizes the mRNA, I sequenced cDNA 
(Figure 14) from heterozygous (elnasa/+) embryos of various stages, from 1 dpf through 5 dpf, and 
7 dpf. The cDNA was obtained from a pooled clutch derived from a WT Tü/AB* to elnasa/sa cross, 
to assure that all embryos were heterozygous (elnasa/+) for the mutation. The wildtype allele (T) 
in heterozygous embryos gets higher as they age, while the mutant allele (A) is reduced and 
disappears by 3 dpf. Wildtype embryos and homozygous elna mutants only display their 
respective alleles. These findings support the conclusion this nonsense mutation activates 
nonsense-mediated decay in a developmentally regulated fashion with close to complete 
elimination of the mutant transcript at relevant developmental stages and therefore is a null 
mutation. 
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3.4    REDUCED ELNA PROTEIN EXPRESSION IN elnasa MUTANTS 
To study the elna protein expression, I performed whole-mount immunostaining in elna+/+ , 
elnasa/+ and elnasa/sa larvae at 7 dpf (n = 3, 5, and 5 respectively). Wildtype had the most 
expression in the blood vessels and the skeleton of the head. Heterozygous elna larvae exhibited 
a decrease in expression, while homozygous mutants lacked elna expression in the head vessels 
and skeleton (Figure 15). 
 
 
Figure 14. Reduced Expression of the elnasa allele 
Embryos heterozygous (Het) for elna show a gradual increase in wildtype allele’s (T) peak (arrow) with 
development and the mutant allele (A) shown in red is gradually reduced. Wildtype embryos at 5 dpf (days 
post fertilization) show only the wildtype allele, and homozygous embryos only display the mutant allele  
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Figure 15. Whole-mount Immunostaining for elna in 7 dpf Embryos 
Wildtype elna+/+, (C,D) elnasa/+, (E,F) elnasa/sa 7dpf larvae in lateral (L) and ventral (V) views for 
immunostaining of elna expression. Expression of elna (fluorescence - bright red) is brightest in 
wildtype embryos (A,B), and decreased in heterozygotes (C,D). Homozygous mutants (E,F) do not 
display specific staining for elna. Scale bar: 200 µm 
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3.5   CIRCULATION DEFECTS IN elnasa MUTANTS  
WT and elnasa/sa embryos at 3 dpf, and larvae at 5 dpf, and 7 dpf were observed for heart 
abnormalities. Embryos were split into groups of fed and unfed at 5 dpf, as this is when the yolk 
has been fully absorbed and feeding is generally started under usual husbandry protocols. 
Mutant embryos fed starting at 5 dpf, displayed reduced blood flow through the heart in 32.5% 
and regurgitation between the atrium and ventricle (or ventricle and BA) in 32.5% of the clutch. 
Reduced blood flow was defined as the presence of fewer red blood cells, a reduction in the 
speed at which the cells flowed through the chambers of the heart or both. Regurgitation was 
not always observed to be associated with reduced blood flow. Mutants also exhibited heart 
looping abnormalities in 42.5%, where the atrium and ventricle were not in the proper 
orientation and position relative to the embryo’s developmental stage (Table 23, Figure 16). This 
experiment was performed once on a set of 100 WT and 100 elnasa/sa embryos. Each set of 100 
was split into two groups of 50 (fed and unfed) at 6 dpf. Further quantification of blood flow will 
need to be conducted and the experiment repeated to determine if the phenotype is observed 
in other embryo clutches.  
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Table 23. Wildtype and elnasa/sa Cardiovascular Developmental Observations 
 
This experiment was performed on n = 100 WT and n = 100 elnasa/sa embryos. Each set of 100 was split into 
two groups of n = 50 (fed and unfed) at 6 dpf. 
 
  
 WT Tü/AB*                  elna
sa/sa 
 3 dpf 5 dpf 
7 dpf   
(fed) 
7 dpf 
(unfed) 3 dpf 5 dpf 
7 dpf  
(fed) 
7 dpf 
(unfed) 
Blood flow 6 4 9 9 26 30 13 17 
Regurgitation 2 1 4 3 14 31 13 27 
Edema 2 2 0 2 9 20 2 1 
Looping Issue 6 2 3 7 12 11 17 7 
Blood pooling 0 2 1 0 2 1 1 0 
Total Survival (n) 100 100 50 48 100 100 40 50 
%                 
Blood flow 6.0% 4.0% 18.0% 18.8% 26.0% 30.0% 32.5% 34.0% 
Regurgitation 2.0% 1.0% 8.0% 6.3% 14.0% 31.0% 32.5% 54.0% 
Edema 2.0% 2.0% 0.0% 4.2% 9.0% 20.0% 5.0% 2.0% 
Looping Issue 6.0% 2.0% 6.0% 14.6% 12.0% 11.0% 42.5% 14.0% 
Blood pooling 0.0% 2.0% 2.0% 0.0% 2.0% 1.0% 2.5% 0.0% 
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Figure 16. Circulation Defects in elnasa/sa mutants. The 7 
dpf values are of fed larvae.  
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Embryos of all three genotypes (wildtype Tü/AB*, elnasa/+, elnasa/sa) were also closely examined 
using a stereo microscope for phenotypic abnormalities including: heart rates, length, swim 
bladder inflation, head and heart structure and blood flow. Heterozygous mutant animals did not 
have any obvious abnormalities. Based on t-tests conducted, there was no significant difference 
between genotypes with respect to swim bladder inflation, length, or head structure. Heart rate 
varied significantly from one clutch to another, but overall there was no correlation with 
genotype at 5 dpf (Figure 18). However, at 7 dpf, there was a slightly but significantly reduced 
heart rate of in elnasa/sa mutants compared to wildtype (p = 0.01698) (Figure 17). Heart rates in 5 
dpf embryos were collected from 7 different clutches and in 7 dpf, WT and elnasa/sa embryo heart 
rates were obtained from single clutches of 42 embryos each.  
Figure 18. Heart Rates at 5 dpf by Genotype 
There was no significant difference between the 
wildtype Tü/AB* (blue), elnasa/+ (yellow) and 
elnasa/sa  (purple) heart rates at 5 dpf. Wildtype 
(n = 25) mean: 135.8 beats per minute, elnasa/+ 
(n = 45) mean: 127.9 beats per minute, elnasa/sa 
(n = 76) mean: 132.1 beats per minute. One-way 
ANOVA p = 0.2246. dpf – days post fertilization. 
Figure 17. Heart rates at 7 dpf by Genotype 
There was a significant difference between the 
wildtype Tü/AB* (blue) and elnasa/sa (purple) 
heart rates at 7 dpf. Wildtype (n = 42) mean: 
128.4 beats per minute, elnasa/sa (n = 42) mean: 
122.1 beats per minute. T-test p = 0.01698. 
dpf – days post fertilization. 
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To follow up on the common observation of blood regurgitation in the hearts of mutant fish, I 
used DIC video microscopy and obtained a closer look at the heart valve structure and function 
in wildtype (WT) and elnasa/sa mutants at 7dpf, at which stage I observed the highest frequency 
of regurgitation. Consistent with this observation elna expression peaks between 6 dpf and 7 dpf 
before decreasing to baseline (Miao et al., 2007). In the resulting videos, mutants display 
ventriculo-bulbar (VB) heart valve regurgitation and irregular formation and movement of the 
valves. Wildtype embryos (Figure 19) appear to have normal blood flow and valves that do not 
appear to have structural or functional defects. In addition to normal appearance of the valves 
in WT, the ventricular contraction appears to be stronger. The ventricle contracts (becomes 
rounder and shorter) and empties completely, while the elnasa/sa mutant ventricle remains 
elongated and does not empty completely, giving the appearance of a weaker contraction (Figure 
20). These results were consistent in two WT clutches (n = 4) but varied between the two mutant 
clutches (n = 8). This could be due to variable compensation by other genetic factors in this 
outbred line, health and natural variability of zebrafish clutches, or as will be discussed later, sex 
differences in adults as seen in human patients with SVAS; males have more severe phenotypes 
than females.  
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Figure 19. WT DIC Video Still of the Ventricular-Bulbar Valve at the End of Systole 
at 7dpf 
Wildtype 7dpf embryo heart (white outline) displays normal blood flow from the 
ventricle (V) to the bulbus arteriosus (BA). Ventricular-bulbar valves (yellow 
outline) appear to have normal development. The V has normal contraction with 
the ventricular lumen narrowing (green) and the V becoming shorter. The BA 
widens (blue) to accept blood cells (purple). Blood flows from the BA to the ventral 
aorta (arrow). dpf – days post fertilization 
Figure 20. elnasa/sa DIC Video Still of the Ventricular-Bulbar Valve at the End of Systole at 
7 dpf 
elnasa/sa mutant 7dpf embryo heart (white outline) displays blood regurgitation from the 
bulbus arteriosus (BA) to the ventricle (V). The Ventricular-bulbar valve (yellow outline) 
appears to have abnormal shape and an incomplete, more narrowed opening. The V has 
reduced contraction with the ventricular lumen and V remaining elongated (green). The 
BA widens (blue) to accept blood cells (purple). Blood flows from the BA to the OFT (arrow), 
but the V and BA do not empty completely of blood cells. dpf – days post fertilization 
V 
BA 
V 
BA 
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To investigate if there were alterations in the size of the cardiac chambers, colonies of 
Tg(myl7:eGFP);Tg(acta2:mCherry) transgenic elnasa/sa mutants and elna+/+ wildtype fish were 
developed. In these transgenic animals, mCherry marks smooth muscle cells in the bulbus 
arteriosus, ventricle, atrium and large arteries, and eGFP marks the myocardium.  Confocal 
microscopy was used to take high-resolution images of the heart at 7 dpf from a clutch of WT (n 
= 6) and a clutch of elnasa/sa mutants (n = 7). Wildtype embryos’ pharyngeal arch arteries were 
consistently more visible than in the mutants, suggesting reduced transcriptional activity of the 
acta2 promoter or incomplete covering of these vessels by smooth muscle cells. Mutant embryos 
displayed abnormalities of the ventricle and BA (Figure 21). Measurements were performed with 
the use of NIS-Elements software. Mutant fish had slightly larger ventricles, and smaller BA, but 
because of substantial variation in the size of these chambers in both groups of fish, these 
differences did not reach statistical significance (Table 24). 
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Table 24. Ventricle and Bulbus Measurements in WT and elnasa/sa transgenic larvae 
Genotype # 
Ventricle Length 
(µm) 
Aspect Ratio 
Ventricle 
(W:L) 
Bulbus Length 
(µm) 
Aspect Ratio 
Bulbus 
(W:L) 
elnasa/sa 1 151.18 0.79 75.39 0.75 
2 164.23 0.57 61.68 1.01 
3 147.56 0.70 57.30 1.08 
4 178.89 0.65 76.51 0.81 
5 168.31 0.51 59.76 1.07 
6 156.73 0.69 75.09 0.79 
7 165.09 0.82 100.62 0.85 
WT (Tü/AB*) 1 165.59 0.62 68.85 0.68 
2 165.16 0.72 81.86 0.57 
3 137.11 0.69 89.10 0.85 
4 133.25 0.65 81.52 0.98 
5 159.54 0.89 91.86 0.70 
6 142.94 0.64 77.59 0.77 
Unpaired T-test  (two-tailed) 
P-value 0.1416 0.6677 0.1952 0.0831 
t, df t=1.584 df=11 t=0.441 df=11 t=1.379 df=11 t=1.906 df=11 
Significant? No No No No 
Mean 
elna^sa/sa 161.71 0.68 72.34 0.91 
Mean WT 
Tu(AB*) 150.60 0.70 81.80 0.76 
Diff. of 
means 11.11 ± 7.019 -0.02595 ± 0.059 -9.461 ± 6.859 0.1502 ± 0.079 
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Figure 21. Abnormalities of the circulatory system in the developing embryo 
Representative images of the ventral view of wildtype Tü/AB* Tg(myl7:eGPF; ca8:mCherry) and elnasa/sa 
Tg(myl7:eGPF; ca8:mCherry) homozygous mutants at 7 dpf. Mutant embryos displayed abnormalities of the 
ventricle (V - yellow), atrium (A - red/orange), bulbus arteriosus (B - red) and ventral aorta (solid arrow). Scale 
bar: 100 µm. dpf – days post fertilization 
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3.6   ELASTIN STAINING IN THE ZEBRAFISH ADULT CARDIOVASCULAR SYSTEM 
Adult hearts were dissected from wildtype Tü/AB*, elnasa/+ and elnasa/sa male and female fish, 
fixed in formalin, embedded in paraffin, sectioned and stained using Hart’s elastin stain to 
visualize elastin deposition and the morphology of the hearts (Figure 22). Histological sections 
show thinner valves in mutants, supporting the notion that the valve form and function observed 
in the DIC videos of mutant embryos remains in adults (Figure 23). 
Figure 22. Hart's Elastin Stain of Adult Zebrafish Hearts 
(A) WT Tü/AB* male adult heart, (B) elnasa/+ female adult heart, (C) elna sa/sa female adult heart. Cardiac 
muscle (yellow) is observed throughout the ventricle (V) with elastin deposition (deep purple) in the bulbus 
arteriosus (BA). The ventricular-bulbar valves (arrow) appear thinner and more irregular in the mutant (C). 
Scale bar: 500 µM.
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3.7    ECOCARDIOGRAPHY IN ADULT FISH 
Echocardiography was done on 18-month-old WT and elnasa/sa adult zebrafish hearts. These 
adults were obtained from the same elnasa/+ in-cross clutch to eliminate husbandry and 
environmental bias that may occur from observing different clutches. Four WT (3♀and 1♂) and 
four elnasa (3♀and 1♂) hearts were examined. The preliminary findings show blood regurgitation 
of the VB valve in the elnasa/sa male (Figure 24). None of the elnasa/sa females nor any of the WT 
hearts showed signs of VB valve regurgitation (Figure 25). Echocardiography of a larger number 
of fish will be necessary to determine if mutant males are more susceptible to developing valve 
disease than females, similar to increased cardiovascular disease in male WBS patients compared 
to females (Sadler et al., 2001).  
 
Figure 23. Hart's Elastin Stain of Adult Zebrafish Hearts – high-magnification view of the VB Valve 
(A) WT Tü/AB* female adult heart, (B) WT Tü/AB* male adult heart, (C) elnasa/sa female adult heart,  
(D) elnasa/sa male adult heart. Histological sections show thinner valves (dotted circle) in mutants (C,D) than 
in wildtype (A,B) adult hearts extracted at 18 months of age. Valve composition also seems to appear more 
cartilaginous in wildtype (A,B) hearts, while mutants (C,D) appear to have a more fibrous and dense 
composition. (BA: bulbus arteriosus. Scale bar: 100 µM) 
A) WT Tü/AB* ♀ B) WT Tü/AB* ♂ C) elna
sa/sa
♀ D) elna
sa/sa
 ♂ 
BA BA BA BA 
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Figure 24. elnasa/sa Echocardiography of a 18mo Male Heart 
Echocardiography of the male elnasa ventricular-bulbar valve (arrow) displays regurgitation. Forward flow of 
blood (dark blue) from ventricle (V) to bulbus arteriosus (BA) and backwards flow (red) from bulbus arteriosus 
towards ventricle. Red and blue colliding circles (light blue line) indicates blood flow regurgitation point.  
Figure 25. Echocardiography of a WT 18mo Female Heart 
Echocardiography of the female WT ventricular-bulbar valve (arrow) displays only forward blood flow (blue) 
from the ventricle (V) to the bulbus arteriosus (BA).  
V BA 
V 
BA 
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3.8    SURVIVAL OF elna MUTANTS TO ADULTHOOD 
The generation of embryos bred from an in-crossed elnasa/+ ♂ x elnasa/+ ♀ breeding resulted in 
341 out of 1,001 embryos surviving to 3 months (Table 25). Genotyping of the 341 survivors 
exhibited a distribution of Mendelian frequencies: elna+/+ – 78 (23%), elnasa/+ – 183 (54%), and 
elnasa/sa – 80 (23%).  A portion of those fish were used for experiments and the new ratios at 3.5 
months were as follows: elna+/+ – 66 (21.6%), elnasa/+ – 171 (56.1%), and elnasa/sa – 68 (22.3%). 
These fish were followed for survival until 18 months of age. 
 
At 18 months of age, homozygous elnasa/sa had the lowest percentage of survival at 19%, but WT 
elna+/+ fish also had poor survival (30%, Table 26) presumably as a result of sub-optimal 
husbandry conditions. Further analysis was done to compare survival between the genotypes 
and also by sex. Despite the log-rank test for survival P value showing significance of 0.0025 by 
genotype comparison, suggesting that survival curves by genotype are different, the log-rank test 
for trend showed no significant trends by genotype or by sex (Table 27).  The log-rank test for 
trend tests a null hypothesis that there is no linear trend between the groups and their median 
survival. With no significant P value for any of the groups, one can conclude that there is no 
significant trend of survival (Figure 26). The relatively low number of fish included in this 
preliminary experiment, as well as the high baseline mortality, reduced the power to detect 
significant genotype or sex effects. 
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Table 25. Survival of Genotyped Zebrafish at 3.5 months 
Genotyped at 3.5 months of age 
(% - Mendelian Ratios) 
Fish Genotyped @3.5 months of age 
Minus # Removed for Experiments  
Genotype # Females # Males 
Total # 
Survived # Females # Males 
Total # 
Survived 
elna+/+ 
54 24 78 
(22.87%) 
48 18 66 
elnasa/+ 
130 53 183 
(53.67%) 124 
47 
171 
elnasa/sa 
54 26 80 
(23.46%) 
48 20 68 
341 305 
Table 26. Survival of Genotyped Zebrafish at 18 months 
Survival of Fish Genotyped @3.5 months 
Minus # Removed for Experiments   
Until 18 months of age       
 (% survival of that genotype) 
Genotype # Females # Males 
Total # 
Survived 
elna+/+ 14 (29%) 6 (33%) 20 (30%) 
elnasa/+ 55(44%) 18 (38%) 72 (43%) 
elnasa/sa 11 (23%) 2 (10%) 13 (19%) 
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Table 27. Survival Analysis of Zebrafish at 18 months 
By Genotype Females Males 
Log-rank test 
Chi square 11.98 8.21 5.309 
P value 0.0025 0.0165 0.0703 
Are the survival curves 
significantly different? Yes Yes No 
Log-rank test for trend 
Chi square 1.948 0.4033 2.608 
P value 0.1628 0.5254 0.1063 
Significant trend? No No No 
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Figure 26. Survival of Zebrafish to 18 months 
(A) Total surviving number of zebrafish by genotype at 18 months of age. (B)
Survival of only female fish by genotype. (C) Survival of only male fish by genotype.
Zebrafish were genotyped at 3.5 months of age, represented by 0 on the X-axis. All
fish were siblings from an elnasa/+ in-cross.
A 
B 
C 
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3.9    VALIDATION OF elnb MUTANT 
For future studies on the developmental function elnb, I obtained F1 embryos with a splice site 
mutation in intron 17 of elnb (elnbsa24024, c.1771+1G>A) from the Sanger Institute Zebrafish 
Mutation Project. The embryos were allowed to reach adulthood and genotyped at 3 months, 
once again using the dCAPS method (Table 5). Sixty out of 101 embryos survived to adulthood, 
and of those, 47% were elnbsa/+ and 53% were elnb+/+. An in-cross series of breeding of elnbsa/+ ♂ 
and ♀ was performed to establish a colony of elnbsa/+ and elnbsa/sa. 24 out of 51 embryos survived 
to adulthood, with 71% elnbsa/+ and 29% were elnb+/+. Due to a lack of any homozygous adults, a 
time series was conducted to determine at what stage the homozygotes were dying. Embryos 
collected and genotyped at 4 dpf, 12 dpf and 25 dpf were acquired from the same breeding clutch 
and showed survival of elnbsa/sa up to 25 dpf (Table 28). The genotype of selected elnb+/+, elnbsa/+ 
and elnbsa/sa progeny was confirmed by DNA sequencing (Figure 27).  
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Table 28. Genotyping Distribution Results of elnb Heterozygous In-cross 
Age # of Embryos Genotype Count (%) 
4 dpf 22 
elnb
+/+ 4 (18) 
elnb
sa/+ 13 (59) 
elnb
sa/sa 5 (23) 
5 dpf 22 
elnb
+/+ 6 (30) 
elnb
sa/+ 14 (70) 
elnb
sa/sa 0 (0) 
12 dpf 25 
elnb
+/+ 2 (8) 
elnb
sa/+ 9 (36) 
elnb
sa/sa 14 (56) 
25 dpf 70 
elnb
+/+ 11 (16) 
elnb
sa/+ 25 (36) 
elnb
sa/sa 34 (48) 
Time Series 
(12 hpf – 5dpf) 
72 total 
for series 
elnb
+/+ 24 (33) 
elnb
sa/+ 30 (42) 
elnb
sa/sa 18 (25) 
3 mph (adults) 24 
elnb
+/+ 7 (29) 
elnb
sa/+ 17 (71) 
elnb
sa/sa 0 (0) 
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Figure 27. gDNA Sequencing of the Mutant Allele in elnb From Embryos at 12dpf 
The peaks of the mutant allele (G - black) and wildtype allele (A - green) are of close to equal height in the 
heterozygous fish. Wildtype and homozygous mutants display their respective alleles. 
3.10 EXPRESSION OF THE elnbsa24024 MUTANT ALLELE 
Because the mutation c.1771+1G>A eliminates a critical G residue of the donor splice site in 
intron 17, I expected that this mutation would interfere with splicing. To uncover the exact splice 
outcome of the mutation, I sequenced cDNA from larvae at 12 dpf (Figure 28). Sequence of the 
heterozygous fish displayed overlapping sequence of exons 17 and 18 in 100% of the sequences, 
indicating an exon 17 skipping induced by the mutation.  
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Figure 28. cDNA Sequencing of Heterozygous elnb Embryos at 12 dpf 
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4.0    DISCUSSION 
In this study I have characterized the genetic and transcript diversity of ELN in both zebrafish 
genes, elna and elnb. Little information was available about the genetic diversity of these gene 
transcripts in zebrafish, despite research that has been done to sequence the genes in their 
entirety, for comparison to each other and among species (Chung et al., 2006; He et al., 2007). 
Diversity helps to explain how adapting genomes contribute to the survival of a species. 
Understanding genetic and transcript variation is also essential for interpreting the functional 
consequences of targeted mutations. Furthermore, this work will help to assess the structural 
similarities and differences between elna and elnb to clarify the function of each gene and 
whether there is any genetic compensation in mutants. Looking at zebrafish with a mutation in 
elna and characterizing the phenotype will help uncover the contribution of elastin to the 
development of the cardiovascular system and the congenital heart defects associated with 
supravalvular aortic stenosis (SVAS). 
4.1    ELASTIN ISOFORM VARIATION AND ITS ROLE IN EVOLUTION 
To characterize genetic and transcript diversity in elna and elnb, cDNA clones were generated 
from WT zebrafish larvae. There was large variation (Table 7) in the sequences compared to 
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already available transcripts in Ensembl, GenBank and in the literature (Chung et al., 2006), with 
the majority being SNVs, along with alternative splicing, numerous length variations and in-dels. 
High sequence variability has also been observed in the human ELN gene (Indik et al., 1987), 
therefore I propose that extensive sequence variation is an evolutionarily conserved feature of 
vertebrate elastin genes, producing a large ensemble of protein isoforms. 
  
A closer look at the SNVs, and comparison to the available transcripts of elna and elnb (24 and 2 
respectively), reveals that the majority of SNVs with accession numbers in the current dbSNP 
database for zebrafish elastin were intronic. The same observation was made from studies in 
avian populations (Backstrom, Fagerberg, & Ellegren, 2008; Strand et al., 2012; Zhan et al., 2015). 
Since introns are not translated, intronic SNVs are considered benign unless they influence the 
splicing of introns or the function of intronic transcriptional regulatory regions. However, SNVs 
found in exons and conserved regions of the elastin genes may prove more useful in studying 
adaptation and fitness among species (Barreiro, Laval, Quach, Patin, & Quintana-Murci, 2008; 
Norrgard  & Schultz, 2008; Zhan et al., 2015)   
 
The density of SNVs has been extensively studied in the human genome, which is useful for 
providing a context to my results.  Overall, the ratio of non-synonymous (missense) to 
synonymous (silent) SNVs in the human genome is 1.18, which is less than half of what is expected 
under a neutral mutation theory (Zhao, Fu, Hewett-Emmett, & Boerwinkle, 2003). A reduced 
missense/silent SNV ratio is considered a measure of natural or purifying selection. By 
comparison, I found a missense/silent ratio of 18/51=0.35 in elna and 41/36=1.14 in elnb. Thus, 
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zebrafish elna is under a considerably stronger purifying selection than an average human gene, 
whereas the selection on elnb is similar to an average human gene. Strong purifying selection on 
elna is consistent with its widespread expression in multiple organs and its orthologous 
relationship to amniote elastin genes. In contrast, weaker purifying selection, and perhaps 
ongoing evolution of elnb may be related to its specialized function in the bulbus arteriosus and 
marked sequence divergence from a putative ancestral elastin gene.   
4.2    ZEBRAFISH ELNA’S FUNCTION AND ROLE IN CARDIOVASCULAR DEVELOPMENT 
Examination of the elnasa point mutation in mRNA from zebrafish embryos reveals that nonsense-
mediated decay (NMD) is activated through developmental regulation. In the elnasa/sa mutant, 
there is elimination of the mutant transcript, creating a null allele. NMD is essential in the 
detection and elimination of premature termination codons (PTCs) for proper gene expression. 
Both mammals (Nagy & Maquat, 1998) and zebrafish (Wittkopp et al., 2009) require an exon-
exon boundary at least 50 basepairs (bp) downstream of the PTC to efficiently activate NMD. 
While the PTC for elnasa is far upstream of the last exon-exon junction, and is thus expected to 
activate NMD, other factors may also play a role in the effectiveness of NMD. Several genes are 
found to make up a group of NMD effectors or surveillance complex, responsible for the 
acceleration of degradation when interacting with other pathway complexes (Behm-Ansmant & 
Izaurralde, 2006), such as the up-frameshift suppressor (UPF) 1, or suppressor with 
morphological effect on genitalia (SMG) proteins SMG1 and SMG7. Studies in zebrafish have 
shown mixed results, in which downregulating of SMG7 did not produce a phenotype, but the 
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downregulation of UPF1 through the use of morpholinos did produce a phenotype and had high 
mortality rates leaves questions as to whether NMD is necessary for embryo viability (Hwang & 
Maquat, 2011; Wittkopp et al., 2009). It is possible that these factors are developmentally 
regulated and thus would explain the late activation of NMD in elna. An alternative explanation 
for the late activation of NMD for the elnasa mutation is that NMD may require a certain threshold 
of mutant mRNA expression to be activated. Thus at developmental stages where elna expression 
is low, such as earlier than 3dpf, the mutant transcripts escape NMD. However, irrespective of 
whether the product of the elnasa allele is degraded by NMD or results in a truncated protein 
lacking most of the coding region, it is expected to be a null allele, which was confirmed by my 
immunostaining results. 
 
In light of evidence for elnasa being a null allele, and signs of strong purifying selection in elna, it 
is surprising that homozygous mutants are viable to adulthood (3 mpf) at Mendelian ratios. A 
possible explanation for the survival of elna mutants is genetic compensation where the 
expression of key genes is altered through development to counteract the phenotypic effects of 
the mutation. This was observed in egfl7 mutants, where genetic compensation was induced by 
deleterious mutations but not by gene knockdowns with the use of morpholinos and CRISPR 
(Rossi et al., 2015). Compensation may occur through the upregulation of a seemingly unrelated 
gene, such as emilin2a, emilin3a and emilin3b in the case of egfl7 mutants, or though the up-
regulation of the paralog of the mutated gene such as vegfab in vegfaa mutants.  
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Possible functional overlap and compensation between elna and elnb will be tested in future 
work with my elnbsa zebrafish line to create a double knockout for elna and elnb. A limitation that 
must be taken into consideration with the generation of a double mutant is lethality. Elastin is 
essential in a wide number of systems in the body and its elimination could prove fatal. Although, 
creation of a heterozygous loss of function elastin mutant, with complete elimination of elnb and 
only one functioning allele of elna, may prove more informative in relation to SVAS and cardiac 
development. In humans SVAS, especially when part of WBS, has variable manifestation of the 
phenotype and is often seen with valvular defects (Sadler et al., 2001) as observed in both the 
elnasa embryos and adults.  
 
In more detailed investigation of how elastin depletion affects cardiovascular development, DIC 
video microscopy of 7dpf embryos showed WT embryos with normal blood flow, ventricular 
contraction and valve development at the VB valve. Mutants displayed blood regurgitation, 
abnormal ventricular contraction and VB valve deformities but with varying degrees of 
abnormalities. When compared to adult hearts using echocardiography, a male elnasa/sa mutant 
had regurgitation, and histological sections show thinner valves in mutants. This is promising 
since cardiovascular deformities are seen more often in human males than in females. A 
limitation of this study is the small number of fish used for imaging and the variability that is 
observed in clutches. This may explain the lack of significant difference between WT and mutant 
heart rates observed as well as in the confocal heart measurements. The preliminary results are 
encouraging considering the variability of penetrance and phenotypes observed in human SVAS, 
thus further work with larger numbers of fish is needed. 
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5.0 CONCLUSIONS 
In summary, the work shows that elastin has been conserved through its ability to adapt to 
evolutionary stressors with extensive sequence variation, and in zebrafish in particular, the 
neofunctionalization of a second elastin gene elnb that may still be evolving. Mutants of elnasa 
have displayed promise to help explain cardiovascular development and detrimental effects of 
elastin mutations in humans with SVAS with a display of valvular abnormalities and regurgitation 
of blood flow in the heart. However, further testing must be done to determine the molecular 
mechanisms of this phenotype and to rule out genetic compensation through the presence of 
two elastin genes, elna and elnb, in zebrafish. 
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6.0  FUTURE WORK 
6.1   ADDITIONAL PHENOTYPE CONFIRMATION 
6.1.1 Additional Look at Valve Structures in Adult Zebrafish 
Based on the preliminary results obtained in the echocardiography and Hart’s elastin staining 
studies, a larger number of adult hearts obtained from the same elnasa/+ in-cross will need to be 
examined to determine the frequency of BA valve defects and other possible cardiac anomalies.  
 
Method: The same protocols established earlier in the dissertation will be used to assure 
consistency in the steps used to obtain results and to maintain the ability to compare preliminary 
data to those in the future. 
 
Expected Results: I expect to see regurgitation and valve developmental abnormalities in at least 
some of the mutant hearts. Given the variability of SVAS in humans, I may find the same in 
zebrafish. 
 
 
 
 
 
 96 
6.1.2 Whole-mount In Situ Time Series of Zebrafish Embryos 
As another method to observe elastin expression in the embryos in addition to the whole-mount 
immunostaining, and to compare results to work done in previous research, a time series in 
embryos using whole-mount in situ hybridization will be conducted. 
 
Method: WT Tü/AB* and elnasa/sa embryos will be collected at 3dpf, 5dpf and 7dpf and treated 
with riboprobes for elna and elnb. Embryos from all 3 time points will be processed and imaged 
simultaneously.  
 
Expected Results: Some overlap of expression of elna and elnb is to be expected at earlier time 
points in WT embryos, but by 7dpf I except to see elnb expressed exclusively in the bulbus 
arteriosus. Mutants of elna should not show any expression. 
6.1.3   Generation of an elnb Mutant Line 
With the possibility of genetic compensation of elna and elnb, and to further the research of 
elnb’s function in zebrafish, a line of elnbsa/sa fish is to be established and crossed with the elnasa/sa 
fish.  
 
Method: Traditional husbandry methods will be used to cross the necessary lines. dCAPs will be 
used for genotyping and observation of the embryos for phenotypic abnormalities will be 
conducted as was done with elna. 
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Expected Results: It is likely that a double knockout of both elna and elnb will not produce a viable 
line of zebrafish for use in adult experiments. Examination of the onset and time course of 
lethality and identifying the cause of death in double mutants will inform our understanding of 
elastin function in zebrafish. For creating a non-lethal model of SVAS a heterozygous loss of 
function of elna and a total loss of elnb may be of interest. 
6.2   MECHANISTIC PATHWAYS ASSOCIATED WITH ELN LOSS 
A better understanding of the connection between elastin mutations and impaired 
cardiovascular development in zebrafish is needed through probing of the molecular 
mechanisms. This work will also help test if these pathways are evolutionarily conserved among 
vertebrates. Prior studies have associated two pathways with elastin deficiency in vertebrates, 
integrin beta 3 (Itgb3) signaling and the Hippo pathways.  
6.2.1   Integrin Beta 3 Signaling and Vessel Development 
Elevated integrin beta 3 (Itgb3) signaling was found to be critical for the development of vessel 
wall thickening in a mouse model of SVAS (Ashish Misra et al., 2016). The integrin signaling 
studies will focus on elna mutants, as this gene appears to be the ortholog of mammalian elastin. 
However, elnb mutants may also be used for comparison, especially if double mutant studies 
suggest a functional overlap. 
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Method:  Immunoblotting for phosphorylated and unphosphorylated focal adhesion kinase 
(FAK) and immunostaining for activated beta 3 integrin will be used quantify integrin signaling. 
In addition, the expression of the Itgb3 paralogs, itgb3a or itgb3b will be assessed by qPCR 
and/or in situ hybridization. For functional studies, Itgb3 signaling will be inhibited using the 
small molecule inhibitor cilengitide  (A. Misra et al., 2016). 
 
Expected Results: If elna is the ortholog of mammalian ELN, I expect elevated Itgb3 signaling 
upon elna deficiency, and a rescue of the mutant phenotype by Itgb3 inhibition. 
6.2.2   Hippo Signaling as a Mechanism of Disease 
A study of elnb in zebrafish observed that knockdown of yap, a signal transducer of the Hippo 
pathway, resulted in a similar expansion of cardiomyocytes into the bulbus arteriosus as elnb 
knockdown did (Moriyama et al., 2016). As this is a correlative result, I am interested in 
obtaining more functional evidence for altered Hippo signaling as a possible mechanism of 
disease in elnb deficiency.  
 
Method:  Immunoblotting for phosphorylated and unphosphorylated Yap and immunostaining 
for Yap/Taz will be used to quantify Hippo signaling. For functional studies, constitutively active 
yap (5SA) mRNA (Asaoka, Hata, Namae, Furutani-Seiki, & Nishina, 2014) will be injected into 
elnb deficient embryos. Alternatively, Hippo signaling will be inhibited using the small molecule 
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inhibitors verteporfin, which inhibits YAP-TEAD interaction and transcriptional activation, or by 
9E1, which inhibits MST1 kinase activity, or by MO knockdown of yap. 
 
Expected Results: If elnb-up-regulates Hippo signaling to facilitate the differentiation of smooth 
muscle cells from heart field progenitors, I expect reduced Hippo signaling in the absence of 
Elnb, a rescue of elnb-related defects by constitutively active yap, and an exacerbated elnb 
phenotype by Hippo inhibition. 
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APPENDIX: TABLES 
Table 29. Primers used in amplifying elna cDNA fragments 
Amp 
# 
Amp 
Name 
Clone 
# 
Amp Sizes 
(bp) Forward Primer Exon Sequence Reverse Primer Exon Sequence 
1 21wb 6 845-860 zf elna I5'1.1s 5' UTR aataaaaccagcacattcgg zf elna E9.1a 13 tgggagatttgagggggt 
2 22.1 6 416-422 zf elna E5.1s 9 agcaaaggctggaaaagc zf elna E16.1a* 16 atttagcagctttggcct 
3 22.2 5 410-1391 zf elna E9.1s 13 agcaaggagtgtttcacgga zf elna E32.1a* 32 tttggcttgagctggtgta 
4 22.3 4 601-712 zf elna E26.1s* 26 caggcaaaagctgctaaat zf elna E36.3a 40 atttaggtggttttgctcca 
22.3a 5 1009-1117 zf elna E23-24.1s* 23-24 tatcctgcgccaggaggt zf elna E36.3a 40 atttaggtggttttgctcca 
5 23.1 6 319-448 zf elna E36.1s 40 tggagcaaaaccacctaaat zf elna E41.1a 45 gccactgggaacagcaat 
23.1a 8 481-670 zf elna E36.1s* 36 tggaggaacaggttttgga zf elna E41.1a 45 gccactgggaacagcaat 
6 23.2 7 1003-1045 zf elna E41.1s* 41 aggagtacctggaggagtg zf elna I56.1a* 3’ UTR aaacgaacaggactgggg 
Amp: amplicon 
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Table 30. Primers used in amplifying elnb cDNA fragments 
Amp 
# 
Amp 
Name 
Clone 
# 
Amp Sizes 
(bp) Forward Primer Exon Sequence Reverse Primer Exon Sequence 
1 4.1w 5 772 zf elnb I5'1.1s 5' UTR cctaattacgtagtgttccttc zf elnb E8.1a 8 gtcctattcctccagtgctaa 
2 4.2b 4 1115 zf elnb E5.3s 5 tacctggtggttttggtgttggt zf elnb E16.1a 16 atatccaccaaacacgccag  
4.2b2 1 893 zf elnb E6-7.1s 6--7 aataggtgtgggtggaaag zf elnb E14.1a 14 cacctggcagaactcctctt 
3 4.4h 6 799-979 zf elnb E12.1s 12 taaagttggaaagcctgggaa zf elnb E22.2a 22 cccaagacctccaccaggaa 
4 15.1b 4 796-1444 zf elnb E20.4s 20 ttctggtttgggagggggtg zf elnb E30.2a 30 aacactccctggtccaaa 
  15.1b2 4 692-1388 zf elnb E20-21.1s 20-21 gtcccgaaggatatgctg zf elnb E30.2a 30 aacactccctggtccaaa 
5 15.2g 5 1080-1293 zf elnb E29.1s 29 atgcagaggcaaaagctc zf elnb E43.1a 43 tcccggcaactccataaa 
6 18.1a 5 456-483 zf elnb E38.1s 38 agttggtggagttggaagtg zf elnb E46.1a 46 ccaattccgctgcctatact 
7 18.2a 7 572-761 zf elnb E45.1s 45 aacattaccaggagccaaacca zf elnb E50.1a 50 tgcctgctccataaactttt 
8 18.3c 6 956-1013 zf elnb E48.1s 48 ttatggtggagctggaag zf elnb E58.2a 3' UTR gcgttgtgacaagttaaggga 
Amp: amplicon 
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Table 31. Primers used to sequence elna cDNA fragments 
Amp 
#, 
Name 
1, 
21wb 
2,  
22.1 
3,  
22.2 
4,  
22.3 
4,  
22.3a 
5,  
23.1 
5,  
23.1a 
6,  
23.2 
Pr
im
er
 N
am
e,
 S
eq
ue
nc
e 
zf elna I5'1.1s 
aataaaaccagcacattcgg 
zf elna 5.1s 
agcaaaggctggaaaagc 
zf elna E9.1s 
agcaaggagtgtttcacgga 
zf elna E26.1s* 
caggcaaaagctgctaaat 
zf elna E23-24.1s* 
tatcctgcgccaggaggt 
zf elna E36.1s 
tggagcaaaaccacctaaat 
zf elna E36.1s* 
tggaggaacaggttttgga 
zf elna E41.1s* 
aggagtacctggaggagtg 
zf elna 9.1a 
accccctcaaatctccca 
zf elna E16.1a* 
atttagcagctttggcct 
zf elna E32.1a* 
tttggcttgagctggtgta 
zf elna E36.3a 
atttaggtggttttgctcca 
zf elna E36.3a 
atttaggtggttttgctcca 
zf elna E41.1a 
gccactgggaacagcaat 
zf elna E41.1a 
gccactgggaacagcaat 
zf elna I56.1a* 
aaacgaacaggactgggg 
M13F -20 (18mer) 
tgtaaaacgacggccagt 
M13F -20 (18mer) 
tgtaaaacgacggccagt 
M13F -20 (18mer) 
tgtaaaacgacggccagt 
M13F -20 (18mer) 
tgtaaaacgacggccagt 
M13F -20 (18mer) 
tgtaaaacgacggccagt 
M13F -20 (18mer) 
tgtaaaacgacggccagt 
M13F -20 (18mer) 
tgtaaaacgacggccagt 
M13F -20 (18mer) 
tgtaaaacgacggccagt 
M13R (17mer) 
caggaaacagctatgac 
M13R (17mer) 
caggaaacagctatgac 
M13R (17mer) 
caggaaacagctatgac 
M13R (17mer) 
caggaaacagctatgac 
M13R (17mer) 
caggaaacagctatgac 
M13R (17mer) 
caggaaacagctatgac 
M13R (17mer) 
caggaaacagctatgac 
M13R (17mer) 
caggaaacagctatgac 
zf elna KE4.1s 
aggaggatatggaggagctg 
zf elna 9.1a 
accccctcaaatctccca 
zf elna 13.2a 
caccagcaccaccaggaaa 
zf elna E29.1s 
ccgggtgttggaggactgta 
zf elna E31.1a* 
aacaatcccagtcctacctg 
zf elna E36.1s* 
tggaggaacaggttttgga 
 zf elna E52.1a 
gatactcaaaccgaccgcc 
zf elna 1.1s 
gtggatatggtggtgctgga 
zf elna 11.1a 
tccagcacctccaccaaagc 
zf elna E16.1a* 
atttagcagctttggcct 
zf elna 34.1a 
ctggtgttgtgcctggact 
zf elna 32-33.1s* 
taaatacggtctaggtgcgg 
  zf elna E50-51.1s* 
caggtgttggactgggaa 
zf elna 5.1s 
agcaaaggctggaaaagc 
zf elna 5.1s 
agcaaaggctggaaaagc 
zf elna E18-19.1s* 
taaatatggtgctgtccctgg 
zf elna E36.3a 
atttaggtggttttgctcca 
zf elna E33.1a* 
acagtcctccaacacccgga 
  zf elna E41.1a 
attgctgttcccagtggc 
   zf elna E25.2a 
attcttcctggtggtgct 
zf elna E27.1s* 
attcttcctggtggtgccg 
  zf elna E51.1s 
aatacggtggtggactgaca 
   zf elna E36.1s* 
tggaggaacaggttttgga 
zf elna E37-38.1s* 
aaatatggtttgggaagtgg 
   
Amp: amplicon 
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Table 32. Primers used to sequence elnb cDNA fragments 
Amp 
#, 
Name 
1,  
4.1w 
2,  
4.2b 
2,  
4.2b2 
3,  
4.4h 
4,  
15.1b 
4,  
15.1b2 
5,  
15.2g 
6,  
18.1a 
7,  
18.2a 
8, 
18.3c 
Pr
im
er
 N
am
e,
 S
eq
ue
nc
e 
zf elnb I5’1.1s 
cctaattacgtagtgttccttc 
zf elnb E5.3s 
tacctggtggttttggtgttggt 
zf elnb E6-7.1s 
aataggtgtgggtggaaag 
zf elnb E12.1s 
taaagttggaaagcctgggaa 
zf elnb E20.4s 
ttctggtttgggagggggtg 
zf elnb E20-21.1s 
gtcccgaaggatatgctg 
zf elnb E29.1s 
atgcagaggcaaaagctc 
zf elnb E38.1s 
agttggtggagttggaagtg 
zf elnb E45.1s 
aacattaccaggagccaaacca 
zf elnb E48.1s 
ttatggtggagctggaag 
zf elnb E8.1a 
gtcctattcctccagtgctaa 
zf elnb E16.1a 
atatccaccaaacacgccag 
zf elnb E14.1a 
cacctggcagaactcctctt 
zf elnb 22.2a 
cccaagacctccaccaggaa 
zf elnb E30.2a 
aacactccctggtccaaa 
zf elnb E30.2a 
aacactccctggtccaaa 
zf elnb E43.1a 
tcccggcaactccataaav 
zf elnb E46.1a 
ccaattccgctgcctatact 
 zf elnb E50.1a 
tgcctgctccataaactttt 
zf elnb E58.2a 
gcgttgtgacaagttaaggga 
M13F -20 (18mer) 
tgtaaaacgacggccagt 
M13F -20 (18mer) 
tgtaaaacgacggccagt 
M13F -20 (18mer) 
tgtaaaacgacggccagt 
M13F -20 (18mer) 
tgtaaaacgacggccagt 
M13F -20 (18mer) 
tgtaaaacgacggccagt 
M13F -20 (18mer) 
tgtaaaacgacggccagt 
M13F -20 (18mer) 
tgtaaaacgacggccagt 
M13F -20 (18mer) 
tgtaaaacgacggccagt 
M13F -20 (18mer) 
tgtaaaacgacggccagt 
M13F -20 (18mer) 
tgtaaaacgacggccagt 
M13R (17mer) 
caggaaacagctatgac 
M13R (17mer) 
caggaaacagctatgac 
M13R (17mer) 
caggaaacagctatgac 
M13R (17mer) 
caggaaacagctatgac 
M13R (17mer) 
caggaaacagctatgac 
M13R (17mer) 
caggaaacagctatgac 
M13R (17mer) 
caggaaacagctatgac 
M13R (17mer) 
caggaaacagctatgac 
M13R (17mer) 
caggaaacagctatgac 
M13R (17mer) 
caggaaacagctatgac 
zf elnb E3.2s 
tggaggtcttgggggaattg 
 zf elnb E10.1s 
tgggccaggaggtatttatc 
zf elnb E18.1s 
ttggtgtaggaggagtacct 
zf elnb E24.2a 
agttcctaaagtcccaccac 
zf elnb E28.1a 
taatccaccaagtccaacacca 
zf elnb E30.1a 
tccttgtccaactccagatcct 
zf elnb E42.1a 
ttcagttttaggtgctttcg 
zf elnb E46.1a 
ccaattccgctgcctatact 
zf elnb E52.1s 
acaaggaggaattggtggag 
zf elnb E5.2s 
aggaattggagcaggtggta 
  zf elnb E20.3s 
tcttggaactggaggacttc 
zf elnb E26.2s 
tgttggacttggtggacta 
zf elnb E24.2a 
agttcctaaagtcccaccac 
zf elnb E38.1s 
agttggtggagttggaagtg 
zf elnb E43.1a 
tcccggcaactccataaa 
zf elnb E46.2a 
aactccaccaactccaccagga 
zf elnb E52.1a 
acaaggaggaattggtggag 
    zf elnb E24.1s 
aacttggaggtggacttgga 
zf elnb E20-21.1s 
gtcccgaaggatatgctg 
zf elnb E30.1s 
ttcctggaggtggatatgga 
zf elnb E45.1s 
aacattaccaggagccaaacca 
zf elnb E46.1s 
agttggtggagttcctggtg 
zf elnb E53.1s 
tttggaggttatgggggagtt 
    zf elnb E24.1a 
aaagtcccaccacgtccaag 
zf elnb E22.2a 
cccaagacctccaccaggaa 
  zf elnb E47.1s 
aaaagttatggtggagctggaa 
zf elnb E57.1a 
tatttggcggcttttgattg 
     zf elnb E25.1a   zf elnb e46.3s 
aaggaggacctggaagtata 
zf elnb E50.2a 
ataaccacctggaccccct 
     zf elnb E26.2s 
tgttggacttggtggacta 
   zf elnb E50.3s 
ttggaggcccaggtggata 
         zf elnb E50-51.1s 
ttggtggccttggttatggt 
         zf elnb E56.1s 
ttttggcggtcctggtgct 
Amp: amplicon 
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Table 33. GenBank accession numbers of cDNA clones 
Submission Name Submission ID (Begins w/ BankIt) 
GenBank Accession 
Number 
elna 
elna 21wb - 1 2010963 KY986538 
elna 21wb - 2 2013293 MF034388 
elna 21wb - 6 2013294 MF034389 
elna 21wb - 8 2013295 MF034390 
elna 21wb - 10 2013287 MF034386 
elna 21wb - 11 2013290 MF034387 
elna 22.1 - 6 2013308 MF034394 
elna 22.1 - 8 2013310 MF034395 
elna 22.1 - 9 2013312 MF034396 
elna 22.1 - 10 2013304 MF034392 
elna 22.1 - 11 2013307 MF034393 
elna 22.1 - 13 2013296 MF034391 
elna 22.2 - 5 2013337 MF034401 
elna 22.2 - 11 2013335 MF034399 
elna 22.2 - 38 2013336 MF034400 
elna 22.2 - 100 2013313 MF034397 
elna 22.2 - 101 2013334 MF034398 
elna 22.3 - 13 2013578 MF039678 
elna 22.3 - 15 2013579 MF039677 
elna 22.3 - 18 2015245 MF101833 
elna 22.3 - 21 2013581 MF039676 
elna 22.3a - 3 2013588 MF039675 
elna 22.3a - 4 2013590 MF039674 
elna 22.3a - 5 2013591 MF039673 
elna 22.3a - 6 2013592 MF039672 
elna 22.3a - 7 2013593 MF039671 
elna 23.1 - 4 2013601 MF039668 
elna 23.1 - 6 2013603 MF039667 
elna 23.1 - 8 2013604 MF039666 
elna 23.1 - 9 2013605 MF039665 
elna 23.1 - 11 2013599 MF039670 
elna 23.1 - 12 2013600 MF039669 
elna 23.1a - 1 2013840 MF039664 
elna 23.1a - 2 2013842 MF039663 
elna 23.1a - 3 2013844 MF039662 
elna 23.1a - 4 2013846 MF039661 
elna 23.1a - 5 2013853 MF039660 
elna 23.1a - 6 2013856 MF039659 
elna 23.1a - 7 2013858 MF039658 
elna 23.1a - 8 2013859 MF039657 
elna 23.2 - 8 2014488 MF067537 
elna 23.2 - 10 2013860 MF067532 
elna 23.2 - 14 2014470 MF067533 
elna 23.2 - 16 2014473 MF067534 
elna 23.2 - 20 2014475 MF067535 
elna 23.2 - 22 2014476 MF067536 
elna 23.2 -17 2014491 MF067538 
 
 
 105 
elnb 
elnb 4.1w - 1 2016080 MF101834 
elnb 4.1w - 3 2016080 MF101835 
elnb 4.1w - 4 2016083 MF101836 
elnb 4.1w - 5 2016083 MF101837 
elnb 4.1w - 6 2016083 MF101838 
elnb 4.2b - 7 2016894 MF118562 
elnb 4.2b2 - 14 2016891 MF118563 
elnb 4.2b2 - 23 2016891 MF118564 
elnb 4.2b2 - 2 2016891 MF118565 
elnb 4.2b2 - 13 2016891 MF118566 
elnb 4.3h - 1 2016895 MF118567 
elnb 4.3h - 2 2016895 MF118568 
elnb 4.3h - 3 2016895 MF118569 
elnb 4.3h - 4 2016895 MF118570 
elnb 4.3h - 5 2016895 MF118571 
elnb 4.3h - 6 2016895 MF118572 
elnb 15.1b - 10 2016901 MF118573 
elnb 15.1b - 13 2016902 MF118574 
elnb 15.1b - 15 2016904 MF118575 
elnb 15.1b - 16 2016905 MF118576 
elnb 15.1b2 - 5 2016906 MF118577 
elnb 15.1b2 - 2 2016906 MF118578 
elnb 15.1b2 - 6 2016906 MF118579 
elnb 15.1b2 - 4 2016906 MF118580 
elnb 15.2g - 2 2016908 MF118581 
elnb 15.2g - 4 2016908 MF118582 
elnb 15.2g - 5 2016908 MF118583 
elnb 15.2g - 6 2016908 MF118584 
elnb 15.2g - 1 Failed Submission * 
elnb 18.1a - 3 2016910 MF118585 
elnb 18.1a - 4 2016910 MF118586 
elnb 18.1a - 5 2016910 MF118587 
elnb 18.1a - 6 2016910 MF118588 
elnb 18.1a - 1 2016910 MF118589 
elnb 18.2a - 2 2016911 MF118590 
elnb 18.2a - 3 2016911 MF118591 
elnb 18.2a - 4 2016911 MF118592 
elnb 18.2a - 5 2016911 MF118593 
elnb 18.2a - 6 2016911 MF118594 
elnb 18.2a -7 2016911 MF118595 
elnb 18.2a - 8 2016911 MF118596 
elnb 18.3c - 3 2016913 MF118597 
elnb 18.3c - 4 2016913 MF118598 
elnb 18.3c - 5 2016913 MF118599 
elnb 18.3c - 6 2016913 MF118600 
elnb 18.3c - 8 2016913 MF118601 
elnb 18.3c - 2 2016913 MF118602 
      * contains premature stop codon, so not allowed to submit to GenBank 
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